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POPULAR SCIENCE SUMMARY OF THE THESIS 
Many of us have had the personal experience of responding to health questionnaires during 
health care visits. Such health questionnaires, called patient-reported outcome measures 
(PROMs), are being used increasingly in health care to capture the health status, problems, or 
symptoms experienced by patients. This information is meant to improve the delivery of 
health care to you, the individual patient, for example by informing the choice of treatment or 
evaluating the effects of treatments. Ideally, the information you provide when responding to 
PROMs in routine health care can be used to improve health and health care, for both 
yourself and others.  
The aim of this thesis was to increase our understanding of the use of PROMs in routine 
health care. Though there are many potential benefits to using routinely collected PROMs, 
research is needed to better understand certain aspects of the methods used for measuring 
health and the ways in which data can be used to improve health and health care. The aim 
was explored by studying a specific case – that of EQ-5D in the Swedish national quality 
registries (NQRs). In the NQRs, health-related information is recorded for specific patient 
populations in routine health care. Most NQRs include PROMs data, and EQ-5D is the most 
frequently used measure. It is a short questionnaire consisting of five questions (regarding 
mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a scale from 
0–100, on which respondents are asked to rate their current health. As a generic PROM,  
EQ-5D can be used to study health outcomes across different patient populations. 
The thesis included four research studies. The first study provided an overview of how  
EQ-5D data were collected in 41 NQRs, and how the results were made available and used. 
The EQ-5D data collected in routine health care settings were used to assess outcomes after 
interventions, in quality indicators, for comparing outcomes across different health care 
providers, for quality improvement, and in consultations with patients. In the second study, 
thoughts expressed by patients with type 1 diabetes who participated in interviews revealed 
that different health aspects, time perspectives, and reference points were considered when 
they reported and valued their own health through different questionnaires, including EQ-5D. 
Data from two different NQRs were used in the third and fourth study, respectively. The third 
study, in which statistical methods were used to evaluate the ability of the EQ-5D instrument 
to capture aspects of health as intended, showed that EQ-5D performed well in measuring the 
self-reported health of patients with amputations of a lower limb. In the fourth study, the 
analyses of EQ-5D data showed that the health of patients who were treated with 
electroconvulsive therapy for major depression generally improved after treatment, and that 
there were no apparent differences between subgroups who received different pulse widths. 
This thesis, based on both methodological and applied research, contributes to our 
understanding of the ways in which EQ-5D data routinely collected in health care may be 
used for different purposes, with the ultimate intention of improving the care and health of 
patients.  
ABSTRACT 
Introduction: Patient-reported outcome measures (PROMs) have been widely used in 
clinical trials and research, for example to monitor the health of specific populations or to 
evaluate treatment effects. In the Swedish national quality registries (NQRs), structured 
individual-level data for specific patient populations are collected in routine health care 
settings. In addition to disease-related information, most NQRs include PROMs data. The 
most common PROM in the NQRs is EQ-5D, which is a generic instrument that can be used 
for measuring and valuing health across different patient populations and disease areas. The  
EQ-5D questionnaire includes questions addressing five dimensions of health (mobility, self-
care, usual activities, pain/discomfort, and anxiety/depression) and a visual analogue scale 
(EQ VAS). In addition, EQ-5D provides an indirect method for obtaining health state values 
and is therefore widely used for the purpose of economic evaluation in health care.   
There has been increasing interest in the use of PROMs in routine health care. Ideally, 
routinely collected PROMs data could be used to inform decisions to improve the quality of 
care and, ultimately, the health of the population. In addition to the potential benefits in 
patient-clinician encounters, aggregate-level PROMs data could for example be used for 
assessing the effectiveness of treatments, for detecting variations between health care 
providers or regions, or as input for decision-making. Real-world cases in which PROMs 
have been widely implemented in routine health care are needed to better understand the 
actual use of routinely collected PROMs data.  
Aim: The overall aim of the thesis was to increase knowledge on the use of PROMs collected 
in routine health care. Using the case of EQ-5D in the Swedish NQRs, this thesis addressed 
the overall aim by investigating current practices of routine collection and use of EQ-5D data, 
and by exploring measurement properties, thoughts behind patients’ responses, and 
applications of EQ-5D as an outcome measure.  
Methods: All four studies included in this thesis examined aspects of making use of EQ-5D 
data, but differed in their designs, samples, data, and analyses. Study I provided an overview 
of how EQ-5D data were collected in the Swedish NQRs, and how the collected EQ-5D data 
were made available and used. Information for each registry was obtained from webpages 
and through personal communication with representatives from the registries. In Study II, 
twenty patients with type 1 diabetes participated in qualitative individual interviews. 
Participants were asked to describe their thoughts out loud while reporting and valuing their 
own health, using EQ-5D-5L, EQ VAS, and time trade-off (TTO). The interviews were 
analyzed using qualitative thematic analysis.  
Study III and Study IV were based on data obtained from two NQRs: the Swedish 
Amputation and Prosthetics Registry and the Swedish National Quality Registry for ECT. In 
Study III, patients responded to either EQ-5D-3L or EQ-5D-5L six months after a major 
lower limb amputation (LLA). The assessment and comparison of the measurement 
properties for the two EQ-5D versions included analyses of feasibility, response patterns, 
 
 
informativity, and convergent and known-group validity. In Study IV, multiple linear 
regression analyses were used to examine the association between pulse width and health-
related quality of life (HRQoL) after electroconvulsive therapy (ECT) in patients with 
unipolar or bipolar major depression.  
Findings: In Study I, the overview of current practices of the collection, presentation, and use 
of EQ-5D data in the NQRs showed that EQ-5D was administered across various populations 
and interventions, and often in combination with disease-specific measures. EQ-5D data were 
most frequently collected in registries targeting patients with conditions related to the 
musculoskeletal system. In Study III, the assessment of measurement properties indicated that 
there were advantages to using EQ-5D-5L over EQ-5D-3L in patients with a major LLA, 
mainly due to improved informativity and validity of the descriptive system.  
In Study II, thoughts expressed during the qualitative interviews revealed some variation in 
the aspects considered and the time perspectives and reference points used when assessing 
one’s own current health using the EQ-5D-5L, EQ VAS, and TTO. Some participants 
expressed a desire to discuss their responses with the health care provider. 
The overview showed several examples of ways in which routinely collected EQ-5D data 
were used, including assessment of interventions, health economic studies, benchmarking, in 
quality indicators, quality improvement, and in patient-clinician encounters. Still, 19 of the 41 
NQRs reported that they were unaware whether the collected EQ-5D data were used for 
follow-up, quality improvement, or decision-making. In Study IV, which was an example of 
the use of EQ-5D data for assessing real-world outcomes associated with an intervention, the 
results showed no robust associations between pulse width and HRQoL after ECT. 
Nevertheless, relatively large mean improvements in HRQoL were observed for patients 
treated with ECT for unipolar or bipolar depression, regardless of the pulse width received.  
Conclusions: The findings from this thesis contribute to the understanding of the use of 
PROMs data routinely collected in the Swedish NQRs, of considerations in the choice of  
EQ-5D version in specific populations, of ways in which EQ-5D data can be used to assess 
specific interventions, and of the interpretations and thoughts behind patient’s responses 
when reporting and valuing their own health. The case of EQ-5D in the Swedish NQRs 
revealed several opportunities of making use of routinely collected PROMs data with the 
ultimate intention to improve health care and patient health. Still, there is potential to increase 
the use of EQ-5D data for follow-up, quality improvement, or decision-making. For future 
implementations of PROMs in routine health care, it may be useful to further explore how 
routinely collected PROMs data could be of most use to patients and other stakeholders, and 
to further explore prerequisites for making use of routinely collected PROMs data at different 
levels of the health care system. 
Key words: patient-reported outcome measures, health-related quality of life, registries, 
routinely collected health data, EQ-5D, time trade-off  
LIST OF SCIENTIFIC PAPERS 
I. Ernstsson O, Janssen MF, Heintz E. Collection and use of EQ-5D for follow-
up, decision-making, and quality improvement in health care – the case of the 
Swedish National Quality Registries. J Patient Rep Outcomes. 2020;16(4):78. 
II. Ernstsson O, Burström K, Heintz E, Mølsted Alvesson H. Reporting and 
valuing one’s own health: a think aloud study using EQ-5D-5L, EQ VAS and 
a time-trade off question among patients with a chronic condition. Health 
Qual Life Outcomes. 2020;18(1):388. 
III. Ernstsson O, Hagberg K, Janssen MF, Bonsel G, Korkmaz S, Zethraeus N, 
Heintz E. Health-related quality of life in patients with lower limb amputation 
– An assessment of the measurement properties of EQ-5D-3L and EQ-5D-5L 
using data from the Swedish Amputation and Prosthetics Registry. 
(Manuscript). 
IV. Ernstsson O, Heintz E, Nordenskjöld A, Johnson JA, Korkmaz S,  
Zethraeus N. Association between pulse width and health-related quality of 
life after electroconvulsive therapy in patients with unipolar or bipolar 
depression: an observational register-based study. (Manuscript). 
 
RELATED PUBLICATIONS 
i.  Ernstsson O, Tinghög P, Alexanderson K, Hillert J, Burström K. The 
External Validity of Mapping MSIS-29 on EQ-5D among individuals with 
Multiple Sclerosis in Sweden. MDM Policy Pract. 2017;2(1): 
2381468317692806. 
ii.  McKay KA, Ernstsson O, Manouchehrinia A, Olsson T, Hillert J. 








1 INTRODUCTION........................................................................................................... 1 
2 BACKGROUND ............................................................................................................. 3 
2.1 Patient-reported outcome measures ...................................................................... 3 
2.1.1 Use of patient-reported outcome measures in routine health care ........... 4 
2.1.2 Methodological aspects of measuring and valuing health ....................... 7 
2.2 EQ-5D – a generic patient-reported outcome measure ........................................ 9 
2.2.1 Measurement properties of EQ-5D ......................................................... 10 
2.3 The case of EQ-5D in the Swedish national quality registries ........................... 11 
2.3.1 Rationale .................................................................................................. 13 
3 RESEARCH AIMS ....................................................................................................... 15 
3.1 Overall aim of the thesis ...................................................................................... 15 
3.2 Aims of the specific studies ................................................................................ 15 
4 MATERIALS AND METHODS ................................................................................. 17 
4.1 Settings and data sources ..................................................................................... 17 
4.2 Primary measures ................................................................................................ 18 
4.3 Overview of the studies ....................................................................................... 22 
4.4 Materials and methods used in the specific studies ............................................ 23 
4.4.1 Study I...................................................................................................... 23 
4.4.2 Study II .................................................................................................... 24 
4.4.3 Study III ................................................................................................... 26 
4.4.4 Study IV ................................................................................................... 28 
4.5 Ethical considerations .......................................................................................... 30 
4.5.1 Ethical review .......................................................................................... 30 
4.5.2 Benefits and risks .................................................................................... 30 
5 RESULTS ...................................................................................................................... 33 
5.1 Study I – Overview of EQ-5D in the Swedish national quality registries ......... 35 
5.2 Study II – Thoughts when reporting and valuing health .................................... 36 
5.3 Study III – Measurement properties of EQ-5D .................................................. 38 
5.4 Study IV – Using EQ-5D to assess outcomes after treatment ........................... 40 
5.4.1 Results of additional analyses ................................................................. 41 
6 DISCUSSION ............................................................................................................... 43 
6.1 The case of EQ-5D in the Swedish national quality registries ........................... 43 
6.2 Prerequisities for making use of data: measurement and interpretability of 
results ................................................................................................................... 44 
6.3 Implications for policy, practice, and research ................................................... 46 
6.4 Methodological considerations ........................................................................... 48 
6.4.1 The case of EQ-5D in the Swedish national quality registries .............. 48 
6.4.2 Primary data collection: Study II ............................................................ 48 
6.4.3 Secondary data collection: Study III and Study IV ................................ 49 
7 CONCLUSIONS ........................................................................................................... 51 
8 ACKNOWLEDGEMENTS .......................................................................................... 53 
9 REFERENCES .............................................................................................................. 57 
10 APPENDICES ............................................................................................................... 63 
10.1 Appendix A – Study I: Template for data collection ......................................... 63 
10.2 Appendix B – Study II: Interview guide ............................................................. 65 





LIST OF ABBREVIATIONS 
ECT Electroconvulsive therapy 
HRQoL Health-related quality of life 
ICD International Classification for Diseases 
IPWRA Inverse-probability-weighted regression adjustment 
LISA Longitudinal integrated database for health insurance and 
labour market studies 
LLA Lower limb amputation 
NQR National quality registry 
PCHC Paretian Classification of Health Change 
PREM Patient-reported experience measure 
PRO Patient-reported outcome 
PROM Patient-reported outcome measure 
QALY Quality-adjusted life year 
Q-ECT Swedish National Quality Registry for ECT 
SALAR Swedish Association of Local Authorities and Regions 
SwedeAmp Swedish Amputation and Prosthetics Registry 
TTO Time trade-off 





Patient-reported outcome measures (PROMs) provide standardized measures of health, as 
assessed directly from a patient’s own perspective. Traditionally, PROMs have been 
integrated as outcome measures in clinical research for assessing health outcomes or 
treatment effects. There is growing interest in the implementation of PROMs in routine health 
care, where they would provide several opportunities of capturing real-world health outcomes 
and effectiveness, for assessing and developing the quality of health care.  
In Sweden, there are more than 100 national quality registries (NQRs) that contain 
individual-level data collected from routine health care settings. The registries may be used 
for monitoring and improving the quality of care for specific target populations, such as 
patients with a certain diagnosis or patients undergoing certain interventions. The registries 
typically include data on both health care processes and outcomes. The majority of the 
registries include one or several disease-specific or generic PROMs, with EQ-5D being the 
most frequently used measure. However, routine collection of PROMs in health care is 
unlikely to contribute to improvements in health care on its own. So far, there is limited 
knowledge regarding the extent to which the routinely collected EQ-5D data are being used 
for purposes that intend to ultimately contribute to improved health care or health outcomes.  
In this thesis, the use of EQ-5D in the Swedish NQRs was applied as a case to better 
understand the use of PROMs collected in routine health care. Specifically, the thesis 
encompassed four research studies which have examined different applications and 
prerequisites for making use of routinely collected EQ-5D data. Hereafter, the four studies 
will be referred to by their roman numerals (Studies I–IV). 
In Study I, we examined current practices of how EQ-5D data were being collected in the 
Swedish NQRs, and how the collected EQ-5D data were made available and used for follow-
up, quality improvement, or decision-making. 
In Studies II and III, some essential prerequisites for making use of data were examined. In 
Study II, qualitative think-aloud interviews were conducted to better understand how patients 
think and reason when reporting and valuing their own health. In Study III, we examined and 
compared the measurement properties of EQ-5D-3L and EQ-5D-5L in patients with a major 
lower limb amputation. 
In Study IV, routinely collected EQ-5D data were used to examine the association between a 
certain treatment parameter and health-related quality of life in patients who were treated 






The goal of a health care system is ultimately to improve the health of the population (1). The 
health care system, which in itself encompasses various systems and processes, may be 
separated into different levels, i.e., the micro-, meso- and macro-levels (2). The micro-level 
of the health care system concerns aspects directly related to the provision of health care to 
individual patients, including the patient-clinician encounter. The meso-level represents the 
part of the health care system addressing management within health care units, hospitals, or 
regions. Lastly, the macro-level cover authorities and national structures for cooperation 
and health policy. Given the fact that the resources available for health care are scarce (3), it 
is essential to prioritize activities that lead to improved health. To assess the performance of 
health care, a central question concerns the extent to which the health care system operates to 
maximize the health of the population (4, 5). Thus, the monitoring of health outcomes plays 
an important role at several levels of the health care system, i.e. for assessing the health of 
individual patients and for assessing the performance and quality of health care. 
Since the health care system should operate to improve the health of individuals, it could be 
argued that the patient perspective on health and health care is central (4). Most processes in 
health care are carried out to achieve outcomes that are important for patients, such as 
survival, reducing symptoms or disability, and improving health-related quality of life  
(HRQoL) (6). Moreover, while certain measures are clinically relevant for understanding the 
status of a condition or disease, measures of patient-reported health status or HRQoL may 
contribute with a perspective on the extent to which a patient is affected by their disease (7).  
Before moving on to the methods for measuring health and HRQoL, the definitions of these 
concepts should be addressed. One widely used definition of health, as specified in the 
Constitution of the World Health Organization (1948), is that “health is a state of complete 
physical, mental and social well-being and not merely the absence of disease or infirmity” 
(8). By contrast, there is no well-established definition of HRQoL. Still, investigations of the 
application of measures of HRQoL seems to reveal an agreement that HRQoL is a 
multidimensional concept (9), and thus several health-related aspects can influence a person’s 
HRQoL. In this thesis, the definition described by Fayers & Machin (2016) is used, namely 
that HRQoL can be seen as “the set of outcomes that contribute to a patient’s well-being or 
overall health, or a summary measure or scale that purports to describe a patient’s overall 
well-being or health” (p.4) (9). 
2.1 PATIENT-REPORTED OUTCOME MEASURES 
Among the many different health outcomes measures available, some are specifically 
constructed to capture health status as assessed from the patient perspective. A patient-
reported outcome (PRO) can be defined as “any report of the status of a patient’s health 
condition that comes directly from the patient, without interpretation of the patient’s response 
by a clinician or anyone else” (10). Standardized measures, PROMs, may be constructed to 
measure various aspects of health and HRQoL, such as physical or social functioning, 
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symptoms, or abilities (9). In this thesis, patient-reported outcome measures (PROMs) and 
patient-reported outcomes (PROs) are used as separate concepts. While the concept of a 
PROM refers to any instrument developed to measure certain health dimensions or 
constructs, PRO refers to a broader concept entailing a variety of health-related outcomes 
reported from the patient perspective. The terms instruments and measures are used 
interchangeably.  
There are a wide range of different PROMs available, developed to capture aspects relevant 
for different target populations and to be used for different purposes. Condition- or disease-
specific measures are intended to capture aspects relevant for patients with a specific 
condition or disease, while generic measures should be broadly applicable and facilitate 
comparison across populations (11). Depending on the purpose and scope of measurements 
performed, several measures – both disease-specific and generic – may be used in 
combination (12). One example of a commonly used generic PROM is EQ-5D, which is a 
short questionnaire consisting of questions addressing five health dimensions (mobility, self-
care, usual activities, pain/discomfort, anxiety/depression) and a visual analogue scale 
(hereafter referred to as EQ VAS) (13, 14).  
2.1.1 Use of patient-reported outcome measures in routine health care 
Importantly for the motivation underlying this thesis, PROMs have been described as 
transitioning from being predominantly used as outcome measures within clinical research to 
more recently being used for planning and managing care, to assure quality of care, monitor 
the health of the population, and to inform policy-making (5). Still, compared to the use of 
PROMs in clinical trials and in research, the routine use of PROMs in clinical practice 
remains less developed, or at least less documented in the scientific literature (6, 7). In theory, 
the opportunities for making use of PROMs data collected in routine health care range from 
the direct benefit when used in the patient-clinician encounters, to the use of PROMs data at 
an aggregate level for quality improvement efforts and for informing decision-making in 
health care. Though the potential benefits of using PROMs addresses all levels of the health 
care system (15), the use of routinely collected PROMs data for assessing the quality of 
health care is at an early stage of development (6). The following sections will, without any 
intention of being exhaustive, provide a brief overview of essential aspects for making use of 
routinely collected PROMs data in health care. These aspects cover the intended and 
observed effects, and facilitators of and barriers to making use of PROMs data.  
When searching for literature on this topic, most previous publications addressing the 
potential benefits of using PROMs in routine health care are published as discussions, 
commentaries, or editorial papers. Still, this literature describes various potential benefits 
from using data, at both the individual and the aggregate level. There are several examples of 
use of individual-level data in patient-clinician encounters at the micro-level of the health 
care system. PROMs data can be used for identifying and prioritizing health problems and/or 
symptoms, screening, shared decision-making, assessing treatment outcomes, and facilitating 
communication between patients and clinicians (6, 12, 16-20). In addition, PROMs can be 
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seen as tools for promoting patient-centered care (16) and may play an important role for 
prioritizing the patient over the disease in clinical practice (7).  
Moreover, routinely collected PROMs data can be analyzed and used at an aggregate level 
for improving health care. Aggregate PROMs data may be used in prognostic models for 
assessing the probabilities of different treatment outcomes for certain interventions (21), 
which could also be integrated in patient-clinician encounters. At the meso- and macro-levels 
of the health care system, data may be used for quality improvement initiatives, for assessing 
and comparing health care providers in terms of effectiveness and quality of care, as input to 
health technology assessments, value-based payments, and for assessing the performance of 
programs or health care delivery systems (6, 16-18, 20).  
2.1.1.1 Intended and observed effects from using PROMs in routine health care 
Although previous sections have listed a number of potential benefits of using PROMs 
routinely in health care, they do not reveal the intended mechanisms and theories explaining 
the ways in which PROMs could improve health care and health outcomes for patients. First 
of all, it should be noted that routine use of PROMs is a complex concept in itself. The 
implementation of PROMs cannot be uniform, as the choice of instrument, the design for data 
collection and feedback, and the use of data need to be purposefully adapted to fit the specific 
health care context and target population. In addition, the implementation of PROMs may be 
further complicated by the fact that different uses of data are intended to achieve different 
goals. As previously mentioned, the goal may be to improve the health of the individual (e.g., 
through screening or shared decision-making) or to improve the quality of health care (e.g., 
by assessing and comparing provider performance). 
Several publications by Greenhalgh and colleagues have used theory-driven approaches to 
address the mechanisms behind the use of PROMs in health care. In 2009, Greenhalgh 
summarized the literature on the extent to which applications of PROMs in clinical practice 
could impact the process and outcomes of care (16). Possible applications were summarized 
in regard to two dimensions: the level of aggregation of data and whether data were used in 
patient consultations or not. For these applications to work as intended, an active process of 
interpreting and acting on the results was considered necessary. For example, the use of 
PROMs could lead to action if the results indicate the presence of a specific problem 
(screening), if necessary changes can be made if a treatment is not working as desired 
(monitoring), if it can be used as a tool for discussing areas that are of priority for the patient, 
or as a tool for making the patient more involved in decisions when weighing benefits and 
risks of different treatment options (16).  
Moreover, based on policy documents, publications, and meetings with stakeholders, 
Greenhalgh and colleagues (2018) developed a theoretical framework explaining the ways in 
which feedback of performance data and PROMs data may stimulate provider behavior to 
improve care and outcomes for patients (22). In summary, feedback on aggregate-level 
PROMs data can stimulate quality improvement initiatives by providing support for patient’s 
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choice of provider, by making providers accountable to commissioners, regulators, and the 
general public, and by providing data for benchmarking that enables providers to compare 
their performance with others. Notably, several contextual factors were considered important, 
such as the timeliness of providing feedback on PROMs data, and the extent to which 
PROMs data were interpreted in the context of other performance data (22). 
It has been suggested that PROMs can be used routinely in clinical practice for both 
evaluating and improving processes and outcomes of health care (23). By searching for 
studies evaluating the actual benefits of PROMs in clinical practice, some literature reviews 
have summarized and assessed the effects on patient care and/or health outcomes (19, 23). In 
summary, controlled trials demonstrate large variations in study designs, selected PROMs, 
patient populations, health care settings, modes of administration, education and involvement 
of health care professionals, the timing, recurrence, and content of feedback, and provision of 
recommendations or support on how to act on the results (19, 23). Variations were also 
observed in the effect measures used, such as changes in provider behaviors, health status, 
satisfaction, and – less frequently – communication, resource use, concordance, and patient 
behavior (23). No firm conclusions could be drawn from the identified studies, due to the 
heterogeneity and limitations in the study designs (19, 23). Still, some results indicated that 
routine use of PROMs in clinical practice might have positive effects on certain process 
variables, e.g. identifying health problems and patient-provider communication (19). 
A large share of the previous research has been focused on use at the individual level, while 
less is known about the use of aggregate-level PROMs data for quality assurance or quality 
improvement, or as an indicator of health care performance (20, 22, 24). One previous 
initiative frequently described in the literature is the NHS PROMs Program. In 2009, the 
National Health Service (NHS) in England implemented a program of routine collection of 
one generic PROM (EQ-5D) and several condition-specific PROMs, before and after four 
elective surgical procedures: hernia repair, hip replacement, knee replacement, and varicose 
veins (25, 26). The intention behind the program was to enhance provider performance by 
publicly presenting PROMs data for different health care providers (26). However, the 
program seemed to have had limited impact on provider performance and patients’ decisions 
regarding their choice of provider (26). It has been argued that collected data remain largely 
unused due to them not being perceived to fit the purpose, and due to challenges in accessing, 
understanding, and acting on the results (27). Furthermore, some criticism relate to the 
difficulties of making meaningful interpretations of data, for example due to a large 
proportion of missing data, or insufficient provision of feedback to clinicians and patients 
(21, 26).  
2.1.1.2 Facilitators and barriers 
Related to the promising opportunities associated with the use of routinely collected PROMs, 
several facilitators and barriers are presented in the literature. Advancements in technology 
has likely been a facilitator for the collection and monitoring of PROMs data in clinical 
practice, through increased use of electronic records and clinical registries (6, 7). The 
 
 7 
possibility of having standardized data collection across providers facilitates use and evidence 
synthesis of data, for purposes such as analyzing real-world outcomes, safety, effectiveness, 
and evaluating the performance of providers (21, 28).  
In a systematic review of qualitative studies, some examples of identified barriers to routine 
data collection of PROMs were the associated workload, use of questionnaires that are not 
user-friendly, and lack of guidelines on how and when to collect, analyze, and interpret the 
data (29). Other barriers include lack of integration between use of data at the individual level 
and the aggregate level, that patients may be unsure of the purpose of completing a PROM 
assessment, survey fatigue, incompatible IT systems, inadequate reporting or feedback of 
PROMs data, and difficulties drawing conclusions due to large proportions of missing data 
(30). Moreover, factors contributing to the limited influence on clinical decision-making 
include that data are often fed back at one time point rather than following the decision 
process longitudinally, and that data are made available in a format inadequate for 
interpretation (31).  
Although the potential impact on decision-making has been mentioned as one of the largest 
potential benefits of routinely collected data, concerns have been raised regarding tensions 
resulting from differing priorities at different levels of the health care system (17, 32). One 
challenge of motivating routine collection only for its use at a higher health care system level 
is the lack of accessible feedback at the micro level, i.e., to health care providers and patients 
(30). Furthermore, the purpose for which data are collected at the clinical level, i.e. providing 
the most appropriate care for an individual patient, may differ from the priorities at higher 
levels of the health care system. The risk for incorrect interpretation has been pointed out 
when making decisions at a system level based on data that have been collected within 
routine health care, for example when there are competing priorities between individual care 
and efficiency (17). At the aggregate level, additional challenges include managing the risk of 
selection bias (e.g., healthier populations), adequate case-mix adjustments, and identifying 
the most suitable timing of measurements in order to make meaningful interpretations (32). 
To overcome the barriers to making use of PROMs data, there has been an emphasis on the 
importance of involving and engaging multiple stakeholders, including for example patients, 
clinicians, researchers, regulators, and policy makers (5, 30). Stakeholder engagement may be 
used for strengthening collaborations and partnerships, for ensuring that the selected 
outcomes correspond to the needs of the stakeholders, and for developing strategies to 
improve the use of PROMs for decision-making (5, 30).  
2.1.2 Methodological aspects of measuring and valuing health  
2.1.2.1 Measurement properties 
In order to make use of the information from a PROM, an important consideration is whether 
the selected measure can provide valid and reliable results. The measurement properties of an 
instrument can be assessed through analyses of validity, reliability, sensitivity, and 
responsiveness (9). Validity represents the ability of an instrument to measure what it is 
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intended to measure and its ability to measure variation in that variable. Analyses of validity 
could for example cover assessments of convergent, divergent, or known-group validity. 
Reliability is assessed by investigating whether measurements are reproducible and 
consistent. Furthermore, the sensitivity of an instrument concerns its ability to detect actual 
differences between individuals or groups, and the responsiveness of an instrument examines 
its ability to detect changes for an individual or group over time (9). In addition to the 
statistical methods used for assessing measurement properties, qualitative methods are 
valuable in several aspects, for example when constructing and testing a questionnaire (9). 
Another consideration relevant for this thesis is analyses of the information captured by an 
instrument. By studying the distributions of responses, the proportions of respondents 
reporting no problems (i.e. ceiling) or extreme problems (i.e. floor) can be examined. In 
addition to the proportions of patients indicating the highest or lowest response categories, 
there are certain analyses (e.g. Shannon’s indices) that facilitate assessment of the 
informativity across all possible response options (33). 
2.1.2.2 Measuring and valuing health for health economic evaluation 
For the purpose of health economic evaluations – in which two or more alternative treatments 
or interventions are compared in terms of their costs and health effects (3) – certain outcome 
measures are preferred. The preferred outcome measure for a cost-utility analysis is the 
quality-adjusted life year (QALY), which combines the value of a health state (also referred 
to as quality weight or utility weight) and the time an individual spends in that health state. 
The health state values are anchored in 0 (dead) and 1 (full health) (3). Some measures enable 
the calculation of negative values, which are thus considered to be worse than dead. 
One way of eliciting health state values is through the use of certain PROMs that provide 
both a health state classification system and an indirect method for assigning values to 
different health states. Some examples of commonly used generic preference-based 
instruments, each covering different aspects of health, are EQ-5D (13, 14), SF-6D (34), and 
HUI (35). These PROMs are commonly referred to as preference-based measures (36) or 
multi-attribute health utility instruments (37), and should, at least in theory, facilitate health 
technology assessment by providing values that are broadly comparable across interventions, 
treatments, and conditions (36). For this category of PROMs, patients are asked to fill out a 
questionnaire, based on which the health state of a patient can be classified. Values are then 
calculated based on previously elicited health state valuations. These sets of values, which 
have been estimated in specific valuation studies, are based on any of the available health 
state valuation methods, for example standard gamble, time trade-off (TTO), rating scale or 
visual analogue scales (VAS) (38). Thus, PROMs that integrate preferences for different 
health states differ from other measures in that they provide different weights for different 
dimensions of health (9).  
One of the most established methods for directly eliciting health state values is TTO, which 
was originally developed by Torrance, Thomas & Sackett (1972) (39). In the TTO method, 
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the respondent is required to make a choice between living in a specified health state for a 
certain time period (e.g. ten years) followed by death or living in full health for a shorter time 
period. The method originally involved that the number of years in full health was varied 
until a point of indifference was reached, in which the respondent considered the two 
alternatives to be equal (39). Since individual interviews are relatively resource-demanding, 
alternative solutions for health state valuations, such as open-ended survey questions, have 
been explored (40). However, it should be noted that different designs and elicitation 
procedures for TTO have been shown to influence the health state values (40, 41). 
In addition to what to value and how to value health, another consideration is the perspective 
of who should value health (42). This is a normative consideration with regard to whether 
health should be valued by individuals in the general population or in specific patient 
populations, and whether the respondents should value their currently experienced health 
states or hypothetical health states that are described to them (43, 44). There are several 
arguments for each positions, including that only patients themselves are able to judge what it 
is like to experience a specific health state, or that societal decisions should be made by the 
general public (38, 44).  
Internationally, there are some variations in the methods recommended for reimbursement 
decisions (45). For example, the National Institute for Health and Care Excellence (NICE) 
requests the use of QALYs as an outcome measure (46). These recommendations specify that 
changes in HRQoL should be directly reported by patients and values should be based on 
public preferences using a choice-based valuation method. In Sweden, the Dental and 
Pharmaceutical Benefits Agency also recommends the use of QALYs, based on either a 
direct or an indirect valuation method, as outcome measure for health economic evaluations 
(47). By contrast, these guidelines specify that values should preferably be elicited from 
persons who are in the specific health state. Thus, from a Swedish perspective, research on 
valuations of experience-based health states are of particular relevance. 
In summary, differences in health state values depending on the measure used will likely 
occur as a result of different methodological choices. At a general level, these choices 
concern the aspects of health covered by the different measures and health state classification 
systems, the valuation methods used, and the perspective applied.  
2.2 EQ-5D – A GENERIC PATIENT-REPORTED OUTCOME MEASURE 
In the late 1980s, EQ-5D was developed to be a concise, generic instrument with the purpose 
to measure, compare and value health status across disease areas (48). The questionnaire 
consists of two parts: a descriptive system covering five health dimensions (mobility,  
self-care, usual activities, pain/discomfort, and anxiety/depression) and the EQ VAS (13, 14). 
There are currently two versions available for adults. The original version, EQ-5D-3L, has 
three severity levels on each of the dimensions covered by the descriptive system and the 
more recently developed version, EQ-5D-5L, has five severity levels (13, 14, 49).  
EQ-5D-5L was developed in 2009 to improve the sensitivity of the instrument and to 
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reduce the ceiling effects (i.e. the proportion reporting no problems) observed in the 
original version (48, 49). There is a crosswalk algorithm that facilitates comparisons when 
different EQ-5D versions have been administered over time or in different populations (50). 
One of the key purposes of constructing EQ-5D was to enable health economic evaluation, 
i.e., to develop an instrument of health status measurement that could also inform resource 
allocation decisions (48). Thus, the EQ-5D instrument provides an indirect method for 
valuing health states. An individual’s responses to the questionnaire result in a descriptive 
health profile, which can be assigned a health state value (EQ-5D index) through the use of a 
value set. EQ-5D value sets are commonly country-specific and developed to reflect the 
preferences of the general population, and most value sets available are based on TTO or 
VAS valuations (51). The first initiative for developing an EQ-5D value set was conducted in 
the UK (52), and the result remains one of the most established and widely used value sets 
internationally (48). Value sets developed more recently have often been based on 
standardized valuation protocols (53).  
Currently, there is no EQ-5D value set developed from the standardized valuation protocol 
available for Sweden. Two studies have been conducted to develop experience-based value 
sets for EQ-5D-3L (54) and EQ-5D-5L (55). The methods used for these two value sets differ 
from those in the valuation protocol in several ways. In the experience-based value sets, 
members of the general population have valued their own current health state. A survey 
question was used, meaning that respondents valued their health without assistance from an 
interviewer. Because an open-ended TTO question was used, respondents did not go through 
iterations before deciding on the number of years in full health they considered to be of equal 
value to living ten years in their current health state. Furthermore, the open-ended TTO 
question did not include a valuation procedure for health states considered worse than dead, 
and therefore, the scale for the index values does not include negative values. 
The use of EQ-5D may serve several purposes. As EQ-5D provides an indirect method for 
valuation of health states that facilitates the calculation of QALYs, the instrument has been 
widely used for the purpose of economic evaluations of health care programs or interventions 
(51). In the early establishment of EQ-5D, the development of the instrument coincided with 
the introduction and more widely adopted use of health technology assessments, which may 
have contributed to the demand for and popularity of collecting EQ-5D data (48). Since then, 
EQ-5D has been used as an outcome measure in clinical trials, observational studies, and 
population health surveys, and more recently, there has been growing interest in investigating 
its usefulness for routine outcome measurement in health care (48).  
2.2.1 Measurement properties of EQ-5D 
The measurement properties of EQ-5D have been evaluated in several patient populations 
and conditions. In a literature review (2018) examining the validity and sensitivity of some of 
the most commonly applied generic preference-based measures, EQ-5D was the instrument 
for which the largest number of studies was identified (36). The studies identified covered 
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conditions across 16 ICD classes (i.e., International Classification of Diseases) and showed 
that EQ-5D performed well across several conditions, such as diabetes and several types of 
cancer, but showed mixed performance for cardiovascular disease and visual disorders, and 
poor performance in hearing impairment, multiple sclerosis, personality disorder, 
schizophrenia, and dementia (36). Although some conditions related to the musculoskeletal 
system have been addressed, no previous study has examined the measurement properties of 
EQ-5D in patients with amputation of a lower limb. 
The newest EQ-5D version, EQ-5D-5L, was developed to address some of the limitations 
observed in the three-level version. A recently published literature review (2020) examining 
studies on the validity, reliability, and responsiveness of EQ-5D-5L identified approximately 
100 studies encompassing a range of general and patient populations (37). The conditions 
most frequently covered by these studies were related to the musculoskeletal system and 
cancer (8 studies each) and respiratory conditions (7 studies). The findings demonstrated 
relatively large variations in the proportion of patients reporting no problems (i.e., ceiling) in 
all dimensions, ranging from 2% to 36%.  
Moreover, the measurement properties of EQ-5D-3L and EQ-5D-5L have been compared in 
more than 40 studies including a variety of populations. The findings from a literature review 
including 24 of these studies showed that both missing values and floor effects were 
generally low (<5%) for both versions (56). Generally, there were indications that EQ-5D-5L 
performs better in several aspects, especially in terms of the distributional characteristics, e.g., 
ceiling effects and informativity of the descriptive system (56, 57). When comparing across 
conditions, the lowest ceiling effects, for both versions, were observed in patients undergoing 
hip and knee replacement (58, 59), orthopedic, psychosomatic, or rheumatic rehabilitation 
(60), and patients with acute stroke (61). Notably, although the literature has increased further 
in recent years, none of the identified studies comparing EQ-5D-3L and EQ-5D-5L has had a 
specific focus on mental health conditions, such as major depression.  
Some concerns have been raised regarding the extent to which EQ-5D is suitable for 
capturing aspects relevant for mental health conditions (62, 63). The literature addressing the 
measurement properties of EQ-5D has specifically focused on conditions such as depression, 
anxiety, bipolar disorder, personality disorder, schizophrenia, and dementia (36, 63). In a 
review of the literature (search until 2011), the overall conclusion from the identified studies 
was that most findings indicated satisfactory validity and responsiveness of EQ-5D-3L in 
patients with depression. By contrast, the limited evidence on the validity of EQ-5D-3L in 
bipolar disorder was mixed, and there were no studies addressing the responsiveness in this 
patient population (63).  
2.3 THE CASE OF EQ-5D IN THE SWEDISH NATIONAL QUALITY 
REGISTRIES 
In this thesis, the use of EQ-5D in the Swedish national quality registries (NQRs) was applied 
as a case to better understand the use of PROMs collected in routine health care. The NQRs 
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contain structured individual-level information and are used for monitoring and improving 
the quality of care for specific patient populations (2, 64). The registries specifically target 
patients with a certain diagnosis, patients undergoing certain interventions or treatments, or 
patients who are at certain risk (2). The vision is that the NQRs should be used “in an 
integrated an active way for continuous learning, improvement, research and management to 
create the best possible health and care together with the individual” (65).  
There are some variations in the structure, size, function, and data registered in the NQRs, as 
a consequence of how health care is organized for specific patient populations (2). Typically, 
individual-level information registered includes basic demographics (e.g., sex, age), process 
measurement and disease-related information (e.g., diagnoses, treatments, complications, 
rehabilitation), and outcomes of care (e.g., survival, clinically relevant outcomes, disease-
specific and generic PROMs). Furthermore, some NQRs contain questions regarding the 
satisfaction and/or experience of care, i.e., patient-reported experience measures (PREMs).  
Historically, the NQRs have usually been established on the initiative of one or several health 
care providers and the first registry was established as early as in the 1970s (64). Currently, 
there are more than 100 Swedish NQRs. Each NQR has a registry organization and a steering 
group involved in the management and development of that registry (2). The registries 
receive logistic and economic support from the Swedish government and the Swedish 
Association of Local Authorities and Regions (SALAR) (64). Although the organization of 
the NQRs is decentralized, there are procedures in place for quality assurance. All NQRs 
send reports and applications for funding on an annual basis and receive feedback on 
performance from an executive committee (12).  
Some aspects of the data coverage should be addressed, as they are important for the 
interpretation of results in this thesis. First, the quality of data entered into the NQRs can be 
evaluated by assessing their completeness and coverage. Completeness may be defined as the 
proportion of all eligible patients in the target population who are included in the registry, and 
coverage as the number of health care units that are affiliated with and provide data to the 
NQR (64). Efforts to ensure high data quality involve automated checks for preventing 
incorrect data entries, reviewing outliers, and comparing data with the population registries 
and medical charts (64). Second, although the NQRs cover a wide range of conditions and 
interventions, it should be noted that most NQRs are focused on specialist care and that there 
are several health conditions for which health care is not followed through an NQR (64). 
Another consideration is that registries are focused on certain conditions or interventions, 
meaning that data on the provision of health care to patients with multiple conditions may be 
recorded in several registries. 
In 2015, Nilsson and colleagues reviewed the inclusion and use of PROMs in the Swedish 
NQRs. Almost 90% of the registries included at least one PROM or PREM (12). Disease-
specific PROMs were most common (more than 60% of the NQRs), followed by generic 
PROMs (more than 45% of the NQRs). Based on a review of generic measures included in 
the registries, the most frequently used instrument was EQ-5D (35 registers), followed by  
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SF-36/RAND-36 (10 registers). From this review, it became clear that the design for data 
collection and use of PROMs data varied substantially between NQRs. Some NQRs 
administered PROMs selectively at specific hospitals or clinics, while other NQRs had 
nationwide collection of PROMs. Furthermore, one of the key messages from this review was 
that data analyses and presentation of PROMs data were still at a basic level (12).  
2.3.1 Rationale 
There are several motives for studying the case of EQ-5D in the Swedish NQRs. Through 
structured nationwide data collection, the NQRs provide opportunities to study real-world 
practices involving use of PROMs collected in routine health care. As a result of the way in 
which the NQRs are structured and organized, PROMs data from the registries could be used 
for several, if not all, the previously mentioned purposes. In addition to discussing the results 
in patient-clinician encounters, the EQ-5D data may be used for different purposes at the 
meso- and macro-level of the health care system as well, e.g., for quality improvement, 
evaluation of real-world outcomes, health economics, and decision making.  
Moreover, among the relatively large number of PROMs and other outcomes included in the 
NQRs, EQ-5D is the PROM most widely adopted across different patient populations and 
interventions. Several NQRs have administered EQ-5D, commonly in combination with other 
disease-specific measures, in for several years, which facilitates analyses of the extent to 
which data have been used for different purposes. Another benefit is the level of detail of 
clinically relevant information reported at the same time point, such as information on 
diagnoses and treatments, intermediate measures, and disease-specific PROs. Ideally, the 
nationwide registration should contribute to the registry population being representative for 
the patient population, which would enable more meaningful interpretations of PROMs data. 
The case and the studies included in this thesis cover several aspects important for the 
understanding of the use of PROMs in routine health care. Study I provided an overview of 
current practices of collection, presentation, and use of EQ-5D data. Study II and Study III 
examined prerequisites for the implementation, interpretation, and use of EQ-5D data. These 
studies were conducted to explore the patient perspective of using EQ-5D-5L, EQ VAS, and 
TTO for reporting and valuing one’s own current health and to assess the measurement 
properties of EQ-5D-3L and EQ-5D-5L in a specific patient population. In Study IV, EQ-5D 
was applied as an outcome measure for analyzing real-world outcomes after a specific 
treatment. In Study III and IV, registry data were obtained from two NQRs that were 
established for the purposes of following and evaluating the health care and outcomes for 
patients receiving specific interventions: patients with lower limb amputations (LLAs) and 
patients treated with electroconvulsive therapy (ECT) for major depression. 
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3 RESEARCH AIMS 
3.1 OVERALL AIM OF THE THESIS 
The overall aim of the thesis was to increase knowledge on the use of patient-reported 
outcome measures (PROMs) collected in routine health care. Using the case of EQ-5D in the 
Swedish national quality registries (NQRs), this thesis addressed the overall aim by 
investigating current practices of routine collection and use of EQ-5D data, and by exploring 
measurement properties, thoughts behind patients’ responses, and applications of EQ-5D as 
an outcome measure.  
3.2 AIMS OF THE SPECIFIC STUDIES 
Specific aims and/or objectives were formulated for each of the studies included in the thesis. 
The following aims were formulated for the specific studies (I–IV): 
I. To increase knowledge on how EQ-5D data are collected within the Swedish 
NQRs, and how the data are made available and are being used in the Swedish 
health care system. 
II. To increase knowledge on how individuals think and reason when reporting and 
valuing their own current health using the EQ-5D-5L descriptive system, 
EQ VAS, and an open-ended TTO question. 
III. To assess the measurement properties of EQ-5D-3L and EQ-5D-5L in patients 
with a major lower limb amputation by comparatively examining the instruments 
in terms of feasibility, distributional characteristics, and validity. 
IV. To examine the association between pulse width and health-related quality of life 
measured within one week after electroconvulsive therapy and at six-month 




4 MATERIALS AND METHODS 
4.1 SETTINGS AND DATA SOURCES 
In this thesis, the case concerned the Swedish NQRs in which EQ-5D data and other PROMs 
have been collected in Swedish routine health care settings. In Sweden, the 21 regions have 
the main responsibility for funding and providing primary and specialist health care to the 
population (66). Health care is primarily funded through taxes, and partly from patient fees 
and other private expenditure (66). There are numerous registries in Sweden that records data 
for the entire population, including registries for monitoring certain aspects of health care. 
However, these mandatory population registries rarely include detailed disease-specific data 
or PROs (12, 64). By contrast, the NQRs contain information on processes and outcomes for 
various patient populations.  
Swedish NQRs. Three of the studies related directly to the Swedish NQRs, either in general or 
for specific registries among them. While the Swedish NQRs should encompass data from 
multiple health care providers (2), most registries rely primarily on data reported from 
specialized health care (64). Registration in the NQRs is voluntary, and there is some 
variation in the ways in which data are recorded in the registries (e.g., when, what, how, and 
by whom). As previously mentioned, there are variations in the contents and structures of the 
NQRs, as a consequence of the way in which health care is organized for certain patient 
populations and medical areas (2). Further, the coverage and completeness of data may vary 
both within registries (e.g., regional differences) and between registries. 
In addition to the registries included in the overview of the collection and use of EQ-5D data 
in Swedish NQRs, two of the studies included in the thesis used data obtained from two 
specific NQRs – the Swedish Amputation and Prosthetics Registry (SwedeAmp) and the 
Swedish National Quality Register for ECT (Q-ECT). 
SwedeAmp was established as an NQR in 2011 (67, 68). In SwedeAmp, patient health data 
are collected to enable assessment of LLAs and their consequences along the health care 
trajectory up to 24 months after surgery. The care processes associated with LLA involve 
several different public and private health care providers (68). With the intention to involve 
all key health care professions, SwedeAmp includes data recorded by surgeons, certified 
prosthetists and orthotists, rehabilitation therapists, and physiotherapists (67). Several PROs 
are used to examine patients’ situation, mobility, function, and HRQoL at 6, 12, and 24 
months after amputation (67). At these three time points, EQ-5D is administered using a 
paper questionnaire either during a health care visit or in a telephone interview. 
At the end of 2018, the registry included data concerning approximately 5,800 patients,  
7,800 amputation surgeries, and 2,000 follow-up registrations (67). In 2019, data were 
reported to the registry from 13 of the 21 regions in Sweden (68). Descriptive statistics 
regarding the characteristics of the patient population showed that approximately 60% were 
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male, the mean age at amputation was 74 years, and 89% of the registrations were for 
unilateral amputations (67). 
Q-ECT, which was established as an NQR in 2011, is used for monitoring compliance to the 
Swedish clinical guidelines for ECT, for quality assurance and for research purposes (69, 70). 
Data from all 21 regions, for approximately 3,600 patients, were recorded in the Q-ECT in 
2019 (70). Several PROMs are used to assess depressive symptoms, remission status, 
memory loss, and HRQoL. Since 2016, the registry administers follow-up assessments six 
months after ECT (70). EQ-5D-3L is administered using paper questionnaires at the 
following time points: before ECT, within one week after ECT, and six months after ECT. 
In 2019, all 47 treating units in Sweden reported data to the Q-ECT (70). The completeness 
of patients included in the registry has improved over time, from 79% in 2012 to over 90% 
since 2014. In 2019, it was estimated that the registry included 93% of all eligible patients 
(70). Data from the registry reveal current treatment practices and use of ECT in Sweden. The 
predominant indications for ECT are major depression and affective disorders (69). In 2019, 
60% of the patients were women and the mean age at treatment was 53 years (70). 
Individual interviews. The interview study was conducted to examine the patient perspective 
of reporting and valuing one’s own health and was thus not directly related to a specific 
NQR. In the interview study, participants were recruited from the Center for Diabetes 
(Stockholm, Sweden), which is a specialist clinic for adults with type 1 diabetes or type 2 
diabetes that is difficult to treat. Patients with type 1 diabetes typically visit the Center for 
Diabetes on an annual basis and care is provided by a team with members from several 
professions, such as physicians, diabetes specialist nurses, dietitians, physical therapists, and 
podiatrists. Importantly for the case used in this thesis, the National Quality Registry for 
Diabetes does not administer EQ-5D to patients included in the registry.  
4.2 PRIMARY MEASURES 
EQ-5D. EQ-5D represents a set of instruments that may be used to describe and value health 
(71). The respondent is asked to self-report his/her current health in the two parts of EQ-5D: a 
descriptive system including five items which cover five health dimensions (mobility, self-
care, usual activities, pain/discomfort, and anxiety/depression) and a vertical VAS (EQ VAS) 
with the end points of 0 (“the worst health state you can imagine”) and 100 (“the best health 
state you can imagine”) (13, 14). The EQ-5D descriptive system was conceptualized to 
measure deviations from full health (49). This is reflected by the response options, which 
correspond to different severity levels of problems experienced. 
Currently, there are two EQ-5D versions available for adult populations: EQ-5D-3L and  
EQ-5D-5L (Table 1) (13, 14, 49). The versions cover the same five dimensions but differ in 
the number of response options. EQ-5D-3L has three severity levels for each dimension (no, 
some, extreme problems/unable) and can theoretically identify 243 health states (35).  
EQ-5D-5L has five severity levels (no, slight, moderate, severe, extreme/unable) and can thus 
identify 3,125 health states (55). In the development of EQ-5D-5L, some adjustments were 
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made to the wording of the descriptive system, e.g., the response option representing extreme 
problems in the mobility dimension was changed from “confined to bed” in EQ-5D-3L to 
“unable to walk about” in EQ-5D-5L (49). 
Table 1. Overview of the dimensions and severity levels covered by the EQ-5D-3L and EQ-5D-5L descriptive 
systems. 
 EQ-5D-3L EQ-5D-5L 
Dimension Level Description Level Description 
MOBILITY 1 No problems in walking about 1 No problems in walking about 
  2 Slight problems in walking about 
2 Some problems in walking about 3 Moderate problems in walking 
about 
  4 Severe problems in walking about 
3 Confined to bed 5 Unable to walk about 
SELF-CARE 1 No problems with self-care 1 No problems washing or dressing 
myself 
  2 Slight problems washing or 
dressing myself 
2 Some problems washing or 
dressing myself 
3 Moderate problems washing or 
dressing myself 
  4 Severe problems washing or 
dressing myself 









1 No problems with performing my 
usual activities 
1 No problems doing my usual 
activities 
  2 Slight problems doing my usual 
activities 
2 Some problems with performing 
my usual activities 
3 Moderate problems doing my 
usual activities 
  4 Severe problems doing my usual 
activities 
3 Unable to perform my usual 
activities 
5 Unable to do my usual activities 
PAIN/ 
DISCOMFORT 
1 No pain or discomfort 1 No pain or discomfort 
  2 Slight pain or discomfort 
2 Moderate pain or discomfort 3 Moderate pain or discomfort 
  4 Severe pain or discomfort 
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3 Extreme pain or discomfort 5 Extreme pain or discomfort 
ANXIETY/ 
DEPRESSION 
1 Not anxious or depressed 1 Not anxious or depressed 
  2 Slightly anxious or depressed 
2 Moderately anxious or depressed 3 Moderately anxious or depressed 
  4 Severely anxious or depressed 
3 Extremely anxious or depressed 5 Extremely anxious or depressed 
For the Swedish versions of EQ-5D-3L and EQ-5D-5L, some additional adjustments of 
wording were made. The dimension for self-care was adjusted from “hygien” (“hygiene”) in 
EQ-5D-3L to “personlig vård” (“personal care/self-care”) in EQ-5D-5L, and the dimension 
for usual activities from “huvudsakliga aktiviter” (“main activities”) in EQ-5D-3L to “vanliga 
aktiviteter” (“usual activities”) in EQ-5D-5L. Furthermore, adjustments were made to level 1 
for self-care, from “Jag behöver ingen hjälp med min dagliga hygien, mat eller påklädning” 
(“I do not need any help with my daily hygiene, food, or clothing”) in EQ-5D-3L to “Jag har 
inga svårigheter med att tvätta eller klä mig” (“I have no problems washing or dressing 
myself”) in EQ-5D-5L. 
Responses to EQ-5D can be summarized in several ways. The EQ-5D health profile is a  
five-digit number that describes a patient’s responses on the severity level of each of the five 
health dimensions (72). For example, health profile 11111 represents no problems in all 
dimensions, while 33333 and 55555 represent extreme problems in all dimensions for  
EQ-5D-3L and EQ-5D-5L responses, respectively. The EQ-5D level sum score is the 
unweighted sum of the five digits. The possible scores range between 5 (best) and 15 (worst) 
for EQ-5D-3L and between 5 (best) and 25 (worst) for EQ-5D-5L (72) . Furthermore, each 
EQ-5D health profile can be assigned a value (sometimes referred to as a quality weight). The 
EQ-5D index value assigns different weights to specific dimensions and severity levels, 
which represents preferences for different health states (usually as stated by members of the 
general population) (72). In this thesis, EQ-5D index values were calculated using value sets 
based on TTO methods: the UK value set for EQ-5D-3L (52) and the crosswalk value set for 
the UK for EQ-5D-5L (50). Both value sets have a possible range from -0.594 to 1 (full 
health).  
Another method for analyzing EQ-5D data is by presenting the Paretian Classification of 
Health Change (PCHC) (72). By comparing individual responses at two measurement points, 
the change in health can be categorized as either improved (if at least one dimension has 
improved and none of the others has worsened), worsened (if at least one dimension has 
worsened and none of the others has improved), no change (if all dimensions are unchanged), 
or mixed (if at least one dimension has improved and at least one dimension has worsened). 
TTO. In this thesis, an open-ended TTO question was used as a direct method for valuing 
one’s own current health. This particular TTO version has been included in general 
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population surveys in Sweden, and the results have been used in studies to develop 
experience-based value sets for EQ-5D-3L and EQ-5D-5L (54, 55).  
The open-ended TTO question presented a horizontal line corresponding to a timeline of  
0–10 years (i.e., each year was marked and labelled, and each half year was marked, but not 
labelled), and read: “Imagine that you are told that you have 10 years left to live. In 
connection with this, you are also told that you can choose to give up some life years to live 
for a shorter time period in full health. Indicate the number of years in full health that would 
be of equal value to 10 years in your current health state.” Below the line, there was an 
additional sentence that read: “(If you think that you currently have full health, you should 




4.3 OVERVIEW OF THE STUDIES 
The thesis includes four separate sub-studies, in which different research design and methods 
were applied. An overview of the materials and methods used in the four studies is presented 
below in Table 2. 
Table 2. Overview of the materials and methods used in the four sub-studies. 
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4.4 MATERIALS AND METHODS USED IN THE SPECIFIC STUDIES 
4.4.1 Study I 
Design. Study I consisted of a descriptive overview based on information provided from 
documents and through personal communication. The purpose of extracting data was to 
summarize current and previous practices and examples of how EQ-5D data are collected, 
made available, and used at different levels of the health care system.  
Sampling. All registries with a license for the use of EQ-5D at the point of data collection 
were included. Thirty-seven NQRs with an EQ-5D license were identified. Since the Swedish 
Neuro Registries had a common license for their ten sub-registries, a total of 46 registries 
were included in the overview. 
Data collection. The data collection was guided by a template developed for the purpose of 
examining the research question addressed in Study I. The template included questions 
regarding the registry in general, the collection of PROM data, administration of PROMs, and 
use of PROM data (Appendix A). In addition to the information about EQ-5D specifically, 
the overview included information on other PROMs (information provided in the 
Supplementary materials to the published article).  
The data collection took place between August 2018 and June 2019. First, information from 
documents (e.g., websites, annual reports) was added to the template for each NQR. Second, 
the information was either confirmed or complemented through personal communication 
with a representative from each NQR. The representative was usually involved in the registry 
organization, steering committee, or specifically in the work with PROMs. The registry 
representative was encouraged to provide examples for each reported use of EQ-5D data. 
Lastly, all representatives had the opportunity to confirm the information before publication, 
for instance with regard to the categorization of how EQ-5D data were collected, made 
available, and used for different purposes. 
Outcomes and definitions. Registries were categorized into disease areas in accordance with 
the classification system developed and used by SALAR (65). In addition, the registries were 
categorized as “diagnosis registries” (i.e. including patients with a specific diagnosis) or 
“intervention registries” (i.e., including patients undergoing specific interventions).  
The ways in which EQ-5D data were collected, presented, and used were categorized based 
on the template for data collection and the information provided from the registries. Target 
groups to whom data were made available included care givers, patients, and other decision-
makers. Further, the categories reflected whether data were presented at an aggregate level 
(i.e., annual reports/websites; research publications; reports adapted specifically for clinics, 
units, or teams; reports targeting patients; other reports) or at an individual level (i.e., 
feedback directed at health care professionals entering data; feedback directed at patients). 
Use of data was categorized based on the use reported by the NQRs, including assessment of 
interventions, health economic studies, quality indicators, benchmarking, quality 
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improvement, and individual consultations with patients. The category for individual patient 
consultations included use of EQ-5D data for screening, monitoring, decision aids, and for 
shared decision-making, as these were considered difficult to separate.  
Certain criteria were used in the categorization of specific use of data. To be categorized as 
used in a quality indicator, EQ-5D data should be included in a quality indicator as defined by 
the registry or some other stakeholder. Further, it should represent a quantitative summary, 
clearly indicate good or poor quality, and be relevant for improvement (73). To be 
categorized as used for benchmarking purposes, the use of EQ-5D data had to involve a 
comparison of results between health care providers, with the purpose of performance 
assessment and to enable identification of improvement needs (74). To be categorized as used 
in quality improvement, EQ-5D data should be used actively in efforts to improve the quality 
of care.  
Data analysis. The information reported from the registry representatives was condensed and 
tabulated after completion of the data collection. Results were summarized and described 
both in terms of descriptive statistics and by presenting examples of reported use of data for 
different purposes. The results regarding collection and use of EQ-5D data were presented by 
registry category and by registry type.  
4.4.2 Study II 
Design. Study II was as a qualitative interview study conducted to better understand 
individual’s thoughts when reporting and valuing their own current health. The interviews 
were guided by think-aloud interview technique and a semi-structured interview guide (75). 
Twenty individual interviews (28–90 min) were conducted in Stockholm, Sweden, during the 
time period February–July 2018.  
Sampling and participants. Using the sampling strategy of purposeful sampling (76), patients 
with type 1 diabetes were recruited to participate in the study. It was expected that individuals 
who were experiencing health problems more likely would consider the trade-off between life 
years and health compared to individuals who were not experiencing any health problems. 
Sampling was performed among patients with type 1 diabetes, as diabetes is a chronic disease 
that impacts everyday life and may affect several dimensions of health. 
The inclusion criteria were men and women between 18 and 70 years who had been 
diagnosed with type 1 diabetes for at least five years. In addition, for feasibility reasons, only 
people speaking Swedish well enough to participate in an interview were included. Study 
participants were recruited through an academic specialist clinic (Center for Diabetes), where 
patients were informed about the study during a regular health care visit. Eligibility was 
assessed by the four specialist nurses involved in the recruitment of participants for this 
study. The recruitment weeks (one week each in January, May, and June 2018) were selected 
based on the clinic’s schedule and the perceived need for additional interviews. Patients who 
expressed willingness to participate were later contacted by telephone for more information 
about the study and for the possibility to ask questions. Out of 77 patients who received 
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information, 41 patients agreed to be contacted and 20 patients (13 men, 7 women) 
participated in the study. 
Measures. The interviews were focused on three health assessments. Participants were asked 
to report or value their own health using the EQ-5D-5L descriptive system, EQ VAS, and an 
open-ended TTO question. Paper versions of the questionnaires (Swedish versions) were 
used. 
Data collection. Three pilot interviews were conducted prior to the main data collection. The 
interviews followed a semi-structured interview guide (Appendix B) including introductory 
questions (e.g., the experience of the onset of symptoms and diagnosis, and experience of 
other diseases), followed by think-aloud exercises and probing questions for 1) the  
EQ-5D-5L descriptive system, 2) EQ VAS, and 3) the TTO question. Participants were given 
paper versions of the questionnaires and were asked to describe their thoughts when 
responding to the three assessments. At the end of their interview, each participant could add 
to or elaborate on their thoughts. Background characteristics for the participants were 
collected through a short survey filled out after the interview. No additional information 
regarding the participants’ health status was collected. All 23 interviews (three pilot 
interviews and 20 interviews in the main data collection phase) were conducted by the thesis 
author (OE). 
The concept of information power, developed by Malterud and colleagues, was used as 
guidance for determining the sample size (i.e., the number of interviews) (77). In this view, 
information power depends on various characteristics of the study design and the data 
collected: study aim (narrow or broad), sample specificity (dense or sparse), established 
theory (applied or not), quality of dialogue (strong or weak), and analysis strategy (case or 
cross-case). In addition to discussing these characteristics, from the 14th interview and 
onwards, the thesis author and the last author of the publication discussed the extent to which 
additional interviews provided new or contradictory findings.  
Data analysis. The audio-recorded interviews were transcribed verbatim. The transcribed 
data were managed and coded manually using NVivo 12 PRO (QSR International Pty Ltd). 
The data were analyzed using a qualitative thematic analysis (78). First, the thesis author 
(OE) conducted the initial coding for each interview separately. The first two interviews were 
read and discussed among the members of the research team. Second, OE reviewed the initial 
coding by re-reading the findings addressing EQ-5D-5L descriptive system, EQ VAS, and 
TTO, separately. In cases of clear overlap, the codes addressing the different assessments 
were combined. When certain findings mainly related to one or two assessments, this was 
indicated in the presentation of results. The analysis was an iterative process developing from 
description of patterns in the data (i.e., codes) to interpretation of meaning (i.e., categories 
and themes). Lastly, the categorization and interpretation were discussed and reconciled 
between the research team members. The quotes presented in the article were translated from 
Swedish into English. 
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4.4.3 Study III 
Design and data source. Study III was a retrospective register-based study. Individual-level 
data for patients who had major LLAs between the years 2010 and 2018 were obtained from 
the SwedeAmp registry (67). Data from the six-month follow-up, supplemented by some 
demographic and clinical information registered in connection with the surgery, were used for 
the assessment of measurement properties.  
The study population consisted of two subsamples of patients who had their six-month 
follow-up during one of two time periods: 1) from 2011 until 2016 – patients who responded 
to EQ-5D-3L (descriptive system), or 2) from 2017 and onwards – patients who responded to 
EQ-5D-5L (descriptive system and EQ VAS). 
Sampling and participants. All patients who were included in SwedeAmp and met the 
inclusion criteria were included in the study. The inclusion criteria were to have had: a 
unilateral major amputation, including transtibial amputation (TTA), transfemoral amputation 
(TFA), or knee disarticulation (KD); primary amputation or re-amputation as surgical 
procedure; a follow-up assessment at six months after surgery, including an EQ-5D-3L or 
EQ-5D-5L measurement. Patients with missing data regarding sex and/or age were excluded. 
Data extracted for this study concerned amputations conducted between 2010 and 2018 and 
follow-ups conducted between 2011 and 2019, at six months after surgery.  
Measures. EQ-5D-3L and EQ-5D-5L were the main measurements of interest for this study. 
EQ-5D data were analyzed and presented in several ways: distribution of responses on the 
five dimensions and EQ VAS (which was only available for EQ-5D-5L); EQ-5D health 
profiles; EQ-5D level sum scores; and EQ-5D index values. Index values were calculated 
using the UK value set for EQ-5D-3L (52) and the cross-walk value set for the UK for  
EQ-5D-5L (50). The two value sets both range from -0.594 to 1 and were chosen for the 
purpose of facilitating comparison between the EQ-5D versions.  
Several disease-specific measures were included. The Locomotor Capabilities Index (LCI-5) 
is a patient-reported assessment of the capability to perform locomotor activities while 
wearing a prosthesis (79). LCI-5 consists of 14 items that are graded on a 5-point ordinal 
scale: 0 (no); 1 (yes, if someone helps me), 2 (yes, if someone is near me), 3 (yes, alone, with 
ambulation aids); 4 (yes, alone, without ambulation aids). Two subscales are constructed to 
represent basic capabilities (7 items) and advanced capabilities (7 items). The prosthetic use 
score assesses the amount of time that a person normally wears their prosthesis during a week 
(80). It is calculated by multiplying the number of days per week (0–7) by the number of 
hours per day (six response options), resulting in a value between 0 (no use) and 100 (each 
day for more than 15 hours). The Swedish translations of these instruments were used. 
The assessment also included single item questions addressing the patient’s overall situation 
as amputee (very good; good; neither good nor bad; bad; very bad), and the occurrence of 
phantom limb pain (none; yes, a little; yes, moderate; yes, a lot) or residual limb pain (none; 
yes, a little; yes, moderate; yes, a lot) during the preceding three months. The questions were 
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administered in Swedish and were translated into English by the members of the research 
team for this publication. 
Statistical analysis. The participant characteristics of the subsamples were compared as 
regards sex, age at amputation, underlying diagnosis leading to the amputation, and 
amputation level. Tests for examining potential statistically significant differences included 
the chi-squared test (nominal categorical variables), the Mann-Whitney U-test (ordinal 
categorical variables), and the independent t-test (continuous variables), at a significance 
level of 0.05. Distribution of responses to the other (disease-specific) outcomes were 
presented for the two subsamples, and between-group differences were analyzed using the 
Mann-Whitney U test. 
The measurement properties were explored through analyses of feasibility, distributional 
characteristics, and validity. For each of these assessments, pre-defined hypotheses were 
tested. Feasibility was defined as the proportion of missing data on the EQ-5D, overall or 
internal missing by dimension. For the analysis of overall missing, we used a variable from 
SwedeAmp indicating respondents who were invited to respond to EQ-5D but did not do so. 
The hypothesis was that a smaller proportion of missing data would be observed for  
EQ-5D-5L responses than for EQ-5D-3L responses. All patients with complete data on the 
EQ-5D descriptive system were included in the following analyses. 
The assessment of distributional characteristics included assessment of response patterns and 
informativity. Response patterns were assessed by examining distributions of responses on 
each health dimension, the proportion of patients reporting no problems, and the number of 
unique health profiles on EQ-5D-3L and EQ-5D-5L. The hypothesis was that a smaller 
proportion would report no problems on EQ-5D-5L than on EQ-5D-3L. In addition, the 
distribution of index values was assessed for EQ-5D-3L and EQ-5D-5L, where a distribution 
with no or few clusters was preferred. Informativity was defined as the ability of an 
instrument to capture all possible health profiles and to discriminate between persons with 
different health status (33). Informativity was assessed using Shannon’s indices per EQ-5D 
dimension (33). There are two indices: Shannon’s index (H′) represents the extent to which 
information is evenly distributed across the possible response options, whereas Shannon’s 
Evenness index (J′) corrects for the number of possible response options (56). The possible 
range of Shannon’s index (H′) is 0–1.58 for EQ-5D-3L and 0–2.32 for EQ-5D-5L. The 
possible range of Shannon’s Evenness index (J′) is 0–1 for both versions. A higher index 
value indicates that more information is being captured. The hypothesis was that a higher 
Shannon’s index (H′) and an equal or higher Shannon’s Evenness index (J′) value would be 
observed for EQ-5D-5L, compared with those for EQ-5D-3L. 
Construct validity was assessed using convergent and known-groups validity. Convergent 
validity assesses whether a person’s response to one instrument is associated with that 
person’s response to another instrument which, at least in theory, should measure the same or 
similar constructs (9). Separate analyses were conducted for the two EQ-5D versions. 
Convergent validity was assessed by examining the strength of association of the specific 
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EQ-5D version and other measures using Spearman’s rank-order correlation. The following 
thresholds were used to interpret the correlation: absent (correlation coefficient rho < 0.2), 
weak (0.2 ≤ rho < 0.35), moderate (0.35 ≤ rho < 0.5), and strong (rho ≥ 0.5) (81). Certain 
relationships were hypothesized on beforehand: EQ-5D mobility and LCI-5; EQ-5D self-care 
and LCI-5; EQ-5D usual activities and LCI-5; EQ-5D mobility and the prosthetic use score; 
EQ-5D pain/discomfort and phantom limb pain; EQ-5D pain/discomfort and residual limb 
pain; EQ-5D level sum score and overall situation as amputee; EQ VAS (for EQ-5D-5L only) 
and overall situation as amputee. For these associations, the hypothesis was to observe equal 
or stronger correlations for EQ-5D-5L compared to the EQ-5D-3L.  
Known-groups validity assesses the extent to which an instrument discriminates between 
groups with anticipated or known differences in the construct covered by the measure that is 
being evaluated (9). The hypothesis was that patients with a higher amputation level 
(TFA/KD) and patients with an amputation due to diabetes and/or vascular disease would 
have worse health. In addition, the two EQ-5D versions were compared in terms of relative 
efficiency (RE), a measure used to evaluate which instrument is most sensitive in detecting 
differences between known groups (9). First, independent t-tests were conducted to compare 
mean index values for groups defined by amputation level and by underlying diagnosis, 
separately for each subsample. Second, a calculation of the RE ratio between the two EQ-5D 
versions were conducted based on the squared t-statistics, using the largest t-statistic as the 
denominator. Thus, the RE ratio had a value between 0 and 1 (strongest).  
The statistical analyses were performed using IBM SPSS Statistics 27.0 (Armonk, NY: IBM 
Corp).  
4.4.4 Study IV 
Design and data sources. Study IV was a retrospective observational register-based study, 
using individual-level data from the Q-ECT registry. In addition, linkages were made to the 
longitudinal integrated database for health insurance and labour market studies (LISA), the 
National Patient Registry, and the Swedish Prescribed Drug Registry. The study design and 
statistical analyses were chosen before data were obtained from the registries [for study 
protocol, see (82)]. 
Sampling and participants. Inclusion criteria were formulated to identify study participants in 
Q-ECT. The Swedish versions of the ICD-10 codes were used to identify certain indications 
for treatment. The inclusion criteria for this study were: adults (≥ 18 years); major unipolar 
depression (ICD-10 codes F32.1–F.32.3, F33.1–F33.3) or bipolar depression (ICD-10 codes 
F31.3–F31.5) as indication for treatment; having received index treatment with unilateral 
electrode placement at first ECT session; and lastly, having EQ-5D measurements (EQ-5D 
index or EQ VAS) at least before and within one week after ECT, and having information on 
pulse width at first ECT session. All patients in Q-ECT who met the inclusion criteria were 
included in the study. If a patient had several treatment series that fulfilled the inclusion 
criteria, only the first treatment was included. 
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Only index treatments were included, meaning that patients in general had received three 
ECT sessions a week until remission, or a physician judged that the maximum treatment 
benefit possible had been achieved within the specific ECT treatment series. All patients 
included in the study population had unilateral electrode placement (d’Elia) in their first ECT 
session. The rationale for this criterion was that the use of unilateral electrode placement is 
standard practice in the treatment of unipolar or bipolar depression in Sweden, and therefore 
is used in approximately 80% of the index treatments registered in Q-ECT (70). 
The ECT treatment series for patients included in the study population were carried out in 
Sweden during 2011–2019. All 21 regions were represented in the obtained data. However, 
the majority of patients in the study population received treatment in one of the three largest 
regions, Stockholm (39%), Västra Götaland (9%), or Skåne (9%). 
Explanatory and outcome variables. The study was conducted to explore the influence of one 
ECT treatment parameter, namely pulse width (expressed in milliseconds [ms]). The main 
explanatory variable was pulse width during the first ECT session. The pulse width (range 
0.25–1.00 ms) was categorized into three subgroups: < 0.5 ms; = 0.5 ms; > 0.5 ms. The 
primary outcome was HRQoL (as assessed using EQ-5D-3L index and/or EQ VAS) within 
one week after ECT. The secondary outcome was HRQoL six months after ECT. EQ-5D-3L 
index values were calculated using the UK value set (52).  
Statistical analysis. Demographic and clinical characteristics were summarized for the total 
sample and for subgroups receiving different pulse widths, to compare their characteristics. 
Between-group differences were tested using the chi-squared test, the chi-squared test for 
trend, or analysis of variance (ANOVA), depending on the data characteristics. Furthermore, 
descriptive statistics were used to compare the study population and the registry population 
for purposes of assessing the generalizability of the study findings.  
For both EQ-5D-3L index and EQ VAS, the means of the differences between baseline and 
within one week after ECT were examined for the total sample using paired t-tests. The 
threshold for a minimally important difference in EQ-5D index was 0.082 (83). Changes in 
health, as assessed using the EQ-5D descriptive system, were analyzed using the PCHC (72). 
The association between pulse width and HRQoL after ECT was examined using multiple 
linear regression analyses, with adjustment for baseline HRQoL (84). Since the Bruesch-
Pagan test indicated presence of heteroscedasticity, ordinary least squares (OLS) regression 
with robust standard errors was used (85). All primary and secondary outcomes were 
examined as continuous variables and tested in separate regression models (and interpreted 
after Bonferroni correction). Covariates were included based on their expected association 
with the explanatory variable and outcome variables. Model 1 included pulse width and 
HRQoL at baseline. In addition, sex, age, and indication were added into Model 2. Lastly, 
concurrent treatment (with a larger anticipated proportion of missing data) was added into the 
final model, Model 3. For all covariates in Model 3, multicollinearity was examined by 
interpreting the variance inflation factor. 
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The statistical analyses were conducted with a significance level of 0.05. After the Bonferroni 
correction, the regression models were interpreted using a significance level of 0.0125. 
Statistical analyses were conducted using IBM SPSS Statistics 27.0 (Armonk, NY: IBM 
Corp) and STATA Statistical Software 15 (College Station, TX: StataCorp LCC). 
Additional analyses. This thesis contains additional analyses for Study IV. Distributions of 
responses before and after ECT were summarized by EQ-5D dimension and EQ VAS score 
for the total sample. Furthermore, to mitigate the possible influence of confounding by 
indication and covariate imbalance between groups (86), the association between pulse width 
and HRQoL was further explored by conducting inverse-probability-weighted regression 
adjustment (IPWRA) for Model 3 (using the teffects ipwra command in STATA). First, a 
multinomial logit regression was applied for the treatment model, i.e., for estimating the 
probabilities of treatment assignment. Variables representing patient characteristics were 
included based on their anticipated impact on being assigned a certain pulse width at first 
ECT (i.e., sex, age, and indication). Second, a multiple linear regression model with robust 
standard error was applied for the outcome model, including all covariates in Model 3. 
Diagnostics, including overlap and covariate balance, were checked. This procedure was 
repeated for all four outcomes, i.e., EQ-5D index and EQ VAS both within one week after 
ECT and six months after ECT.  
4.5 ETHICAL CONSIDERATIONS 
4.5.1 Ethical review  
Approval was granted from an ethical review board for the research studies including 
personal data: Study II (Regional Ethical Review Board in Stockholm, Ref. no: 2017/526-31; 
2017/2123-32), Study III (Regional Ethical Review Board in Stockholm, Ref. no: 2018/1137-
31/2), and Study IV (Regional Ethical Review Board in Uppsala, Ref. no: 2014/174; 
2014/174/1; 2014/174/2; 2020-05154). Ethical review was not required for Study I, as it did 
not include any personal data or sensitive information. 
4.5.2 Benefits and risks 
The sub-studies differed in design, type of data, and involvement of participants. Thus, 
different potential benefits and risks were identified for each study.  
Study I. The potential risks were considered limited, as no personal information was 
processed. The overview of how EQ-5D data were collected, made available, and used was 
associated with benefits both for the understanding of the context of the thesis and as a 
contribution to the relatively limited scientific literature on routine collection and use of 
PROMs in health care.  
Study II. The study used qualitative interview data gathered with active participation from 
study participants. Participation in the study was not expected to lead to any direct benefits 
for the participants, except the possible perception that their experiences were shared. Ethical 
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considerations in this study included voluntary participation, informed consent, 
confidentiality, and correct processing of personal data. In the first recruitment step, 
participants were given written information about the study. In addition to information about 
the purpose and procedure of the research study, the written information specified that: 
participation was voluntary and participants had the right to withdraw at any time; the study 
had been approved by an ethical review board; personal data would be processed and stored 
by Karolinska Institutet; the health care provided would not be affected by their decision to 
participate or not. The written information also specified compensation for participation. 
Participants had the opportunity to ask questions in the second stage of recruitment, when 
contacted by telephone by the thesis author. The nurses who initiated the recruitment were 
not informed about who participated in the study. All study participants gave informed 
consent prior to their interview.  
Another identified risk was related to the sensitive topic, i.e. that questions could provoke 
thoughts and reflections both during and after the interview. The choices regarding the study 
sample and some inclusion criteria (i.e. age and years since diagnosis) were made to avoid 
having interviews coincide with a new diagnosis or treatment. Participants were informed 
through the written study information that the interview would include questions about 
health, disease, life, and death. Lastly, all participants received contact details to a counsellor 
at the end of the interview.  
Studies III–IV. The register-based studies were not expected to lead to any direct benefits for 
the study participants. Still, making use of collected data may contribute to indirect benefits 
for patients and health care professionals who invest time and effort in recording health data. 
Register data could also be considered to be used well for when included in methodological 
research (as in Study III), since data collection solely for that purpose is resource-demanding 
and carries a risk of limited benefits for the patients and others involved. Precautions for 
managing the identified potential risks of the register-based studies included secure 




The findings from each of the four sub-studies are summarized in this section. All four sub-
studies are relevant to the case used in this thesis: the collection and use of EQ-5D in the 
Swedish NQRs. The study-specific research questions were examined for a number of patient 
populations, including a variety of patient populations and interventions covered by the 
NQRs included in the overview, and the specific study samples. The demographic 
characteristics for each of the study samples are summarized in Table 3. No such information 
is presented for Study I, as it entailed information about the 41 registries that included EQ-5D 
data at the time of data collection. 
Table 3. Overview of demographic characteristics, by study samples, for Studies II–IV.   
 Study II Study III Study IV 
Patient population 
Patients with  
type 1 diabetes 
Patients with a major  
lower limb amputation 
Patients with unipolar  
or bipolar depression 
Total, n 20 685 5,046 
Women, n (%) 7 (35) 221 (32) 3,008 (60) 
Men, n (%) 13 (65) 464 (68) 2,038 (40) 
Age, mean (SD) 46 (15) 72 (14) 53 (18) 
   18–39 years, n (%) 8 (40) 17 (3) 1,317 (26) 
   40–59 years, n (%) 6 (30) 90 (13) 1,703 (34) 
   60–79 years, n (%) 6 (30) 366 (53) 1,665 (33) 
   80–100 years, n (%) 0 (0) 212 (31) 361 (7) 
The following samples and subsamples were included in the studies: Study II included 20 
patients with type 1 diabetes; Study III included 685 patients with a major LLA; Study IV 
included 5,046 patients who were treated with ECT for unipolar or bipolar depression.  
EQ-5D results were available for all study participants in Study II–IV (Table 4). In Study II, 
EQ-5D index and EQ VAS scores were in the ranges 0.50–1 and 30–95, respectively, at the 
time of the interviews. For the two subsamples in Study III, the mean EQ-5D-3L and  
EQ-5D-5L index values were 0.55 and 0.53 at the six-month follow-up after a major LLA. In 
Study IV, the mean EQ-5D-3L index values increased from 0.31 before ECT to 0.71 one 












5.1 STUDY I – OVERVIEW OF EQ-5D IN THE SWEDISH NATIONAL QUALITY 
REGISTRIES 
Forty-one of the 46 NQRs with an EQ-5D license administered EQ-5D to measure patient-
reported health in their registry population. Ten of the registries were sub-registries of the 
Swedish Neuro Registries. The 41 registries targeted patient populations with a variety of 
diagnoses and/or interventions. Most frequently, EQ-5D was measured and collected in 
registries targeting conditions related to the musculoskeletal system (n=11), the nervous 
system (n=9), the circulatory system (n=7), and less frequently in registries targeting cancer 
(n=3), psychiatry (n=3), pediatrics (n=2), infection (n=2), other areas (n=2), the endocrine 
organs (n=1), or the stomach and intestines (n=1).  
Registries used different modes of administration and times of measurement in the collection 
of EQ-5D data. Twenty-four registries administered EQ-5D-3L and 16 administered  
EQ-5D-5L (Table 5). Examples of different times of measurement included before and after 
intervention, continuous measurement at specified time-points, or once per patient, and 
examples of different modes of administration included paper questionnaires or web 
questionnaires. All but one of the 41 registries also administered other PROs, such as disease-
specific PROMs or questions regarding general health, symptoms, function, use of assistive 
devices, or working ability. 
Table 5. Numbers of registries reporting collection of EQ-5D-3L or EQ-5D-5L (2018), by category and type. 
 Total, n Intervention registries, n Diagnosis registries, n 
  EQ-5D-3L EQ-5D-5L EQ-5D-3L EQ-5D-5L 
Musculoskeletal system 11 4 4 2 1 
Nervous system 1 9 2 0 4 3 
Circulatory system 7 1 1 4 1 
Cancer 3 0 0 1 2 
Psychiatry 3 2 0 1 0 
Infection 2 0 0 0 2 
Other areas 2 0 0 2 0 
Endocrine organs 1 0 0 1 0 
Pediatrics 2 1 0 0 0 1 
Stomach and intestines 1 0 0 0 1 
All registry categories 40 9 5 15 11 
1 Of which six were sub-registries within the Swedish Neuro Registries  
2 In addition, one registry collected EQ-5D-Y, the child-friendly EQ-5D version, only. 
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EQ-5D data from the NQRs were summarized and presented at either an individual or an 
aggregate level. The most frequently reported channel for presenting results was through the 
registries’ annual reports or websites (n=29). Other examples of how aggregate data were 
made available included reports of aggregate data directed at clinics, units, or professional 
teams (n=20), and scientific publications (n=18). Several registries made individual-level data 
available to health care professionals (n=17) and/or patients (n=12).  
The overview shows that EQ-5D data collected in the Swedish NQRs were being used in 
quality indicators, for assessment of interventions, health economic studies, quality 
improvement, benchmarking, and/or in individual patient consultations (Figure 1). Twenty-
two registries reported use of EQ-5D data, while 19 registries reported that data were not 
used, or that they were unaware of whether data were used. Use of EQ-5D data was reported 
by 12 of the 26 diagnosis registries (46%) and 10 of the 15 (67%) intervention registries.  
 
Figure 1. Numbers and distribution of 22 registries reporting use of EQ-5D data for different purposes. Note that 
each registry reporting use of EQ-5D data could report several categories of use. 
More specifically, in regard to the use of EQ-5D data in quality indicators and for 
benchmarking, registries commonly reported that data from these analyses were publicly 
available in the registries’ own reports or online tools, and on national platforms. One 
example of such a platform is “Health care in numbers” (“Vården i siffror”), which is an 
online tool for quality improvement initiatives, with continuous updates concerning indicators 
of quality and efficiency in Swedish health care (87). 
5.2 STUDY II – THOUGHTS WHEN REPORTING AND VALUING HEALTH  
The thematic analysis of how individuals think and reason when reporting their own current 
health resulted in two themes (i–ii) based on four categories (a–d). When reporting and 
valuing one’s own current health using EQ-5D-5L, EQ VAS, and TTO, the thought processes 
of individuals interpreting and completing these assessments involved (i) personalizing 
questions and considering what aspects to include in the response, and (ii) using reference 
points and comparators to enable assessment of their own health. The categories described 
how interview participants approached the assessments by (a) contextualizing and 
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interpreting instructions, (b) relating the questions to their own health, (c) using different 
recall periods and time perspectives, and (d) using personal, interpersonal, or normative 
comparators. 
In summarizing the findings, some patterns should be highlighted. First, participants reflected 
on the purpose and usefulness of results as part of the process of deciding what aspects to 
consider in their response. Participants personalized the questions when interpreting the 
questionnaires, for example by linking certain aspects of their own health to the presumed 
purpose of the questionnaire. Participants actively reasoned regarding what aspects to include 
or not in their assessment. This process raised concerns about the subjectivity of the questions 
and, by extension, the interpretability and usefulness of the results. Some participants 
described wanting to explain their responses, either through follow-up questions or in 
dialogue with their health care provider. 
”If someone notices it and say ‘why are you 75 instead of 100?’ Then you can talk 
about it. But it requires that someone looks at that damn questionnaire that no one 
looks at, when you fill it out in the reception and like, check, I have filled out this 
form a hundred times and no one cares. Eh. So that’s part of it.. So, like, you need an 
interview to capture it. Or that someone who sits there really understands – oh what 
does this mean?” [Participant 3] 
Second, different time perspectives and recall periods were applied for the three assessments. 
When responding to the EQ-5D-5L descriptive system and EQ VAS, participants generally 
considered their health either at the present time or retrospectively over a longer period of 
time. When responding to the TTO, participants described thoughts of their future. These 
thoughts included expectations of their future health status, their subjective life expectancy, 
and activities and goals that they desired to fulfil. Fifteen participants did not trade any life 
years to live for a shorter period in full health. Reasons for this decision included that one’s 
experienced problems were considered manageable and wanting to have as much time as 
possible to support and/or spend time with children, family, and friends. 
“Yeah, but the thing about death and that I only have ten years left to live, okay, then 
I start counting how old my children will be... And all that... How long will I get to be 
with my husband (…) And how can I maximize that?” [Participant 16] 
Third, different interpretations and reasoning were expressed in regard to the terms 
“best imaginable health” in EQ VAS and “full health” in the TTO question. 
Different reference points were applied in the EQ VAS assessment (e.g., an ideal 
person or personal circumstances). Still, the concept of full health in the TTO 
question was considered difficult to define, imagine, and relate to. Two participants 




”You never get that opportunity... To live in full health, that is not an option that 
exists in reality. Like, what you can do is to live as good as you can with the time you 
have left, I think” [Participant 18] 
Lastly, some findings were more clearly linked to one or another of the assessments. 
Especially in regard to the descriptive system, some participants expressed a desire to discuss 
aspects associated with health rather than aspects associated with problems or disease. In 
addition, one of the most prominent examples was that the impact on others was more clearly 
integrated in the response to the TTO. 
“But here it is definitely- I want to have as much time as possible with, eh.. My 
partner, my family (…) So then it is no longer just based on me, but here is it also 
about… Giving time to others. While the two first are definitely how I experience 
myself. Or mostly focused on that I would say (…) But this was definitely something  
I kept in mind, that others should be given time as well” [Participant 11] 
5.3 STUDY III – MEASUREMENT PROPERTIES OF EQ-5D 
In the study sample, which included 685 patients, more than two thirds were men (68%). 
Patients had either a TTA (below-knee amputation) (76%), a TFA (above-knee amputation) 
(18%), or a KD (knee disarticulation) (7%). The majority of patients had diabetes and/or 
vascular disease as the underlying diagnosis (83%) and the mean age at amputation was 72 
years (range 20–100).  
Two subsamples were used for the assessment and comparison of measurement properties: 
EQ-5D-3L respondents (n=425) and EQ-5D-5L respondents (n=260). The subsamples did 
not differ significantly in the distributions of sex, age, amputation procedure, level of 
amputation, or underlying diagnosis (p>0.05). Regarding PROMs and PROs, no significant 
between-group differences were observed regarding the overall situation as amputee, LCI-5, 
or the prosthetic use score (p>0.05). However, a larger proportion of the EQ-5D-5L 
respondents reported phantom limb pain (p<0.001) and residual limb pain (p<0.05). 
Measurement properties of EQ-5D-3L and EQ-5D-5L. The study sample for assessing the 
distributional characteristics and validity included 685 patients with complete EQ-5D data at 
follow-up six months after amputation. An additional 15 patients (73% men, mean age 73.9 
years) were included only for the analysis of feasibility (i.e., analysis of missing data) of  
EQ-5D-3L and EQ-5D-5L. The feasibility of EQ-5D-3L and EQ-5D-5L, as assessed based 
on the proportion of complete responses to the descriptive system, was 98% for both 
versions. Ten patients in the EQ-5D-3L subsample and 5 patients in the EQ-5D-5L 
subsample had no, or an incomplete, EQ-5D measurement. 
Regarding the distributional characteristics of responses to the EQ-5D-3L and EQ-5D-5L, 
patients most frequently reported problems related to mobility (78% and 75%), 
pain/discomfort (70% and 75%), and usual activities (61% and 74%). Less frequent reporting 
of problems was observed for anxiety/depression (44% and 52%) and self-care (38% and 
48%). Severe or extreme problems with mobility were reported by 23% on EQ-5D-5L and 
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only 7% on EQ-5D-3L. The proportion of responses indicating no problems in any of the 
dimensions (i.e. the ceiling) was 7% for EQ-5D-3L and 6% for EQ-5D-5L. No problems 
were most frequently reported in the self-care dimension for both EQ-5D-3L (62%) and  
EQ-5D-5L respondents (52%) (Table 6). The mean EQ-5D index was 0.55 (SD 0.31) for  
EQ-5D-3L respondents and 0.53 (SD 0.31) for EQ-5D-5L respondents.  
Table 6. Numbers and proportions of patients reporting no problems (ceiling) in each of the health dimensions 
six months after a major lower limb amputation, by subsamples of EQ-5D-3L and EQ-5D-5L respondents. 
 EQ-5D-3L sample EQ-5D-5L sample 
 n=425 n=260 
Mobility, n (%)  95 (22.4) 64 (24.6) 
Self-care, n (%) 262 (61.6) 136 (52.3) 
Usual activities, n (%) 168 (39.5) 65 (25.0) 
Pain/discomfort, n (%) 129 (30.4) 69 (26.5) 
Anxiety/depression, n (%) 240 (56.5) 124 (47.7) 
Furthermore, EQ-5D-5L showed higher Shannon’s index values (H′) and Shannon’s 
Evenness index values (J′) than EQ-5D-3L across all dimensions. The largest difference 
between the versions was observed in the mobility dimension: Shannon’s index (H′) was 1.09 
for EQ-5D-3L and 2.21 for EQ-5D-5L, and Shannon’s Evenness index (J′) was 0.69 for  
EQ-5D-5L and 0.95 for EQ-5D-5L. The mobility dimension was of particular interest due to 
the change from “confined to bed” in EQ-5D-3L to “unable to walk about” in EQ-5D-5L. 
When analyzing the EQ-5D-3L dimensions only, the lowest informativity was observed for 
the mobility dimension, in which 71% of the respondents used severity level 2 (moderate 
problems). 
The statistical analysis of convergent validity showed correlations between the two EQ-5D 
versions and other measures that were in line with the hypotheses. For both versions, the 
dimensions of mobility and self-care showed moderate to strong correlations (rho ≥ 0.42) 
with LCI-5 scores. By comparison, the correlations between usual activities and LCI-5 scores 
were slightly weaker, i.e., rho -0.31 to -0.32 for EQ-5D-3L and -0.34 to -0.36 for EQ-5D-5L 
(p<0.01). For both EQ-5D versions, moderate correlations were observed between the 
mobility dimension and the prosthetic use score and between the pain/discomfort dimension 
and the questions related to phantom and residual limb pain. A moderate correlation was also 
found between the anxiety/depression dimension and the overall situation as amputee, which 
was not covered by the pre-specified hypotheses. Although only available for EQ-5D-5L, the 
EQ VAS showed a moderate correlation with the overall situation as amputee (rho 0.46). 
The interpretation of findings related to known-groups validity was also based on hypotheses. 
On average, worse HRQoL was observed among women, patients of older age, and patients 
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with a higher amputation level. However, none of the EQ-5D versions indicated differences 
in HRQoL between subgroups by underlying diagnosis. Only EQ-5D-5L could discriminate 
between subgroups defined by different amputation levels (RE ratio 0.538). A summary of 
the findings is presented in Table 7. 
Table 7. Summary of the findings related to feasibility, distributional characteristics, and validity of EQ-5D-3L 
and EQ-5D-5L in patients with a major lower limb amputation. 
 EQ-5D-3L EQ-5D-5L Summary of findings 
Feasibility / / 
The proportions of complete responses on the 
descriptive system were similar (97.7% for  
EQ-5D-3L versus 98.1% for EQ-5D-5L) 
Ceiling (i.e., proportion 
reporting no problems in 
all five dimensions) 
/ / 
The proportions were similar (6.6% for EQ-5D-3L 
and 5.8% for EQ-5D-5L) 
Informativity  – + 
The informativity was higher for EQ-5D-5L than 
for EQ-5D-3L across all dimensions 
Convergent validity – + 
The correlations between EQ-5D and other 
disease-specific measures were generally stronger 
for EQ-5D-5L than for EQ-5D-3L 
Known-groups validity – + 
Only EQ-5D-5L was able to discriminate between 
groups defined by amputation level;  
Neither the EQ-5D-3L nor EQ-5D-5L index 
values were able to discriminate between groups 
defined by underlying diagnosis 
Note: + indicates higher or better results; – indicates lower or worse results, / indicates similar results. 
In this table, the results for two separate subsamples (EQ-5D-3L and EQ-5D-5L respondents) are summarized 
and compared, based on response patterns and to what extent the results are in line with the study hypotheses.  
5.4 STUDY IV – USING EQ-5D TO ASSESS OUTCOMES AFTER TREATMENT 
In Study IV, the study sample included 5,046 patients with unipolar (82%) or bipolar 
depression (18%). Similar to the Q-ECT registry population, the study sample included 
approximately 60% women and 40% men, and the mean age was 53 years (SD 18.2). EQ-5D 
index and EQ VAS measurements before and within one week after ECT were extracted for 
4,990 and 4,914 patients, respectively (4,858 patients completed both). A follow-up 
measurement at six months after ECT was available for a subsample (EQ-5D index, n=730; 
EQ VAS, n=851).  
Patients received a pulse width of either <0.5 ms (15%), 0.5 ms (72%), or >0.5 ms (13%) at 
their first ECT session. There were statistically significant differences between the subgroups 
in terms of the distribution of sex, age, and the presence or absence of psychotic features 
(p<0.05). The subsample receiving <0.5 ms pulse width was on average younger and 
included a larger proportion of women, compared to the other two subsamples (p<0.0001). In 
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addition, the proportion of patients with psychotic features was smaller among those 
receiving <0.5 ms (12%) compared with the other two subsamples (18–19%) (p<0.0001). 
Furthermore, there were statistically significant differences in the proportion of patients with 
concurrent use of medication, e.g., antidepressants (p=0.032), antipsychotics (p<0.0001), 
benzodiazepines (p<0.0001), and antiepileptics (p=0.020).  
Before ECT, the mean EQ-5D index value was 0.31 (SD 0.29) and the mean EQ VAS score 
was 26 (SD 18.91) for the total sample. Within one week after ECT, the corresponding 
numbers were 0.71 (SD 0.28) for EQ-5D index and 61 (SD 23.32) for EQ VAS. Per 
subgroup, the mean improvements between the measurements were 0.38 (<0.5 ms), 0.40 (0.5 
ms), and 0.36 (>0.5 ms) for EQ-5D index, and 33 (<0.5 ms) and 35 (0.5 ms and >0.5 ms) for 
EQ VAS. 
Association between pulse width and HRQoL after ECT. The regression analyses showed no 
statistically significant associations between pulse width and HRQoL within one week after 
ECT, after adjusting for HRQoL at baseline, sex, age, depression diagnosis, psychotic 
features, and concurrent medications (p>0.05). After adjusting for these characteristics, the 
regression analysis for the secondary outcomes six months after ECT showed significantly 
lower EQ-5D index values (β -0.089) for the subsample receiving 0.5 ms, compared with 
those receiving <0.5 ms (p=0.011). The result of the corresponding analysis for EQ VAS six 
months after ECT was not statistically significant (p>0.05).  
5.4.1 Results of additional analyses 
Association between pulse width and HRQoL after ECT. As an additional analysis to further 
examine the association between pulse width and HRQoL after ECT, IPWRA was explored. 
For Model 3, these analysis showed non-significant associations (for pulse width 0.5 ms and 
>0.5 ms compared to the reference <0.5 ms) for all primary and secondary outcomes, 
including EQ-5D index at six months (β -0.047; 95% CI -0.112–0.019) (Appendix C). 
Changes in HRQoL from before ECT to one week after ECT. The response distributions for 
the total sample showed overall improvements across all health dimensions within one week 
after ECT (Figures 2–3), in particular in the dimensions for usual activities and 
anxiety/depression. Overall, improvements were observed also for EQ VAS (Figure 4). Still, 
approximately one out of ten patients reported extreme problems with anxiety/depression 





Figure 2. Distributions of responses (%) to the EQ-5D descriptive system before ECT (n=4,990).  
Note: MO = mobility, SC = self-care, UA = usual activities, PD = pain/discomfort, AD = anxiety/depression. 
 
Figure 3. Distributions of responses (%) to the EQ-5D descriptive system one week after ECT (n=4,990).  
Note: MO = mobility, SC = self-care, UA = usual activities, PD = pain/discomfort, AD = anxiety/depression. 
 
Figure 4. Distributions of EQ VAS responses (%) before ECT (n=4,914) and one week after ECT (n=4,914). 
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This thesis aimed to increase knowledge on the use of PROMs routinely collected in health 
care by examining a specific case: the use of EQ-5D routinely collected in the Swedish 
NQRs. The results revealed that EQ-5D data were collected in 41 Swedish NQRs, covering a 
variety of patient populations and interventions. Most registries had administered EQ-5D for 
several years, and two had collected EQ-5D data for 20 years. EQ-5D was most frequently 
administered in registries targeting conditions related to the musculoskeletal system. For 
patients with amputation of a lower limb, the results demonstrated several advantages of the 
measurement properties of EQ-5D-5L compared to the EQ-5D-3L. The use of EQ-5D data 
covered several purposes, including assessment of interventions, health economic studies, 
quality indicators, benchmarking, quality improvement, and use at the individual patient 
level. When applying EQ-5D as an outcome measure for examining HRQoL after ECT in 
patients with unipolar or bipolar depression, no robust association was found between a 
certain treatment parameter (pulse width) and patients’ HRQoL after ECT. Lastly, the thesis 
also presented findings regarding how patients think and reason when reporting and valuing 
their own current health using EQ-5D-5L, EQ VAS, and TTO. Some variation was revealed 
in the individual interpretation of the questionnaires, for example with regard to what aspects 
to include in the assessment and use of different time perspectives and comparators. 
6.1 THE CASE OF EQ-5D IN THE SWEDISH NATIONAL QUALITY 
REGISTRIES  
The results from this thesis showed that EQ-5D was administered for a variety of conditions 
and interventions in Swedish health care, often in combination with other PROs. In the early 
development of EQ-5D, the instrument was intended to be used alongside other measures, as 
well as for facilitating resource allocation decisions (48). Based on the studies included in this 
thesis, some benefits of using EQ-5D in combination with other measures may be 
highlighted. As could be expected, most measures for patients with LLA focused specifically 
on mobility and physical functioning, while most measures for patients with major depression 
specifically focused on depressive symptoms and memory. In these two cases, the generic 
EQ-5D might contribute to a more holistic perspective on the impact on a patient’s HRQoL, 
by combining both effects and adverse effects related to physical and mental aspects in one 
measure. Still, though the wide implementation of EQ-5D across populations facilitates 
between-group comparison, the usefulness of EQ-5D for specific purposes will likely vary 
depending on the patient population and the medical area. For example, the timing of 
measurement may vary depending on whether the purpose of a registry is to follow a defined 
population or a specific intervention.  
The case of EQ-5D in the Swedish NQRs provided an opportunity to study the use of 
PROMs across several different levels of the health care system, including both use at the 
individual patient level in clinical practice and aggregate-level analyses. Although the NQRs 
have an existing infrastructure for nationwide data collection in various populations and for 
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various conditions, the thesis showed that some challenges in making use of data remain. 
Nineteen registries reported that EQ-5D data were not being used for follow-up, quality 
improvement, or decision-making. Furthermore, the thesis demonstrated few examples of 
how routinely collected EQ-5D data were used for decision-making at higher levels of the 
health care system. One important learning outcome from this case is that routine data 
collection alone is an insufficient strategy for realizing the potential benefits of PROMs data.  
While reflecting on the results from this case, an essential consideration for implementing a 
PROM in routine health care is the extent to which a selected measure can enable for 
meaningful and actionable interpretations. One of the main potential benefits of 
implementing a generic preference-based measure, as opposed to other PROMs, lies in its 
many areas of use for analysis at an aggregate level and across conditions. The thesis 
revealed examples of EQ-5D data being included in individual patient-clinician encounters 
and in quality indicators, assessments of interventions, health economic studies, quality 
improvement, and benchmarking. However, some aspects of the use of PROMs in routine 
health care may have been missed in this case due to the specific focus on one PROM. Since 
several PROMs are often needed to capture aspects that are relevant for patient health, one 
could also expect that several PROMs and/or other outcome measures would be needed to 
achieve all potential benefits, from micro- to meso- and macro-level analyses. Thus, the 
purpose of and intended mechanisms for making use of data could guide the choice of 
measure and design in future implementations of PROMs in routine health care.  
6.2 PREREQUISITIES FOR MAKING USE OF DATA: MEASUREMENT AND 
INTERPRETABILITY OF RESULTS 
The extent to which useful interpretations can be made depend on the ability of the selected 
outcome measure to provide valid and reliable results (9). Ideally, a PROM should have 
satisfactory measurement properties and cover aspects that are relevant for the specific patient 
group of interest. As shown in Study I, EQ-5D is commonly implemented in areas related to 
the musculoskeletal system, and several registries, including the SwedeAmp registry, have 
shifted from administering EQ-5D-3L to administering EQ-5D-5L. In patients with an LLA, 
satisfactory measurement properties were demonstrated for both EQ-5D-3L and EQ-5D-5L, 
with indications of better performance for EQ-5D-5L, especially in terms of improved 
informativity and validity. Thus, these results indicated that the change from EQ-5D-3L from 
EQ-5D-5L have improved the measurement of patients’ HRQoL following major LLA in the 
registry. At the same time, the performance of the instrument used for comparison should 
also be considered. Several disease-specific measures were used for comparison, including 
both established PROMs and single-item questions developed specifically for SwedeAmp. 
The disease-specific LCI-5 has been evaluated in terms of validity, reliability, responsiveness, 
and sensitivity in patients participating in prosthetic training after a unilateral LLA (79, 88), 
and the measurement properties of the prosthetic use score and the overall situation as an 
amputee were assessed during their development (80). 
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In Study IV, EQ-5D was applied as an outcome measure for examining the association 
between pulse width and HRQoL after ECT. Although concerns have been raised regarding 
the use of EQ-5D for measuring other conditions related to mental health (62), satisfactory 
measurement properties have been demonstrated in patients with major depression (63). A 
related concern is the extent to which EQ-5D captures aspects relevant for patients. A 
previously conducted interview study presented a variety of aspects important for the HRQoL 
of patients with various mental health conditions, including well-being and ill-being; physical 
health; self-perception; hope and hopelessness; autonomy, control, and choice; relationships 
and belonging; and activity (89). In the design of Study IV, EQ VAS was included as an 
additional primary outcome measure to allow aspects beyond the five health dimensions to be 
captured. Still, both the outcomes based on direct assessments from the patient (EQ VAS) 
and the outcomes based on stated preferences (EQ-5D index) led to the same conclusions. 
In addition to the measurement properties, the methods and perspectives applied for health 
state valuation are central to the interpretation of EQ-5D index values. These values provide 
information valuable for the purpose of health economic evaluations. Still, there are several 
other ways in which EQ-5D data may be presented (72), which could provide more detailed 
information regarding the changes in specific dimensions of health. For example, in patients 
undergoing ECT for unipolar or bipolar major depression, the results one week after 
treatment demonstrated relatively large improvements in EQ-5D index (mean difference 
0.40), EQ VAS (mean difference 34), and when combining the dimensions in a PCHC 
analysis (73% improved). 
Importantly for the interpretation of EQ-5D results, the thesis revealed novel findings 
regarding patients’ thoughts when reporting and valuing their current health using EQ-5D-5L, 
EQ VAS, and TTO. One interesting finding was the shift in time perspective when 
responding to different questionnaires: from considering current or past health when 
responding to EQ-5D and EQ VAS, to considering the future when responding to the TTO 
question. However, it is challenging to draw conclusions based on this single study regarding 
whether this is a general finding for the TTO valuation method or a specific finding for 
patients with a chronic condition. If expectations on future health are clearly integrated into 
valuations of all currently experienced health states, the characteristics of the participants and 
the conditions (e.g., the expected progress of disease) may greatly impact the health state 
values. By contrast, a previous study exploring the influence of different responder 
characteristics found no association between the expectations of future health and TTO 
valuations (90).  
Overall, it is challenging to draw conclusions regarding the extent to which the findings from 
Study II are transferable to other TTO designs. The perspective of valuations (i.e. currently 
experienced health or hypothetical health states) is only one of several sources of variation 
between studies. Examples of other methodological choices include the time frame, the 
phrasing of the question(s), the elicitation procedure, the mode of administration, and the use 
of visual aids (40, 41, 91). Furthermore, it should be noted that the open-ended question 
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neither had iterations to assist the participant to find a point of indifference, nor presented the 
possibility to value health states as being worse than dead. Still, some similarities with 
previous findings regarding valuations of described health states should be noted. For 
example, a common finding was the use of both own experiences and imagined health states 
for reference (92). Furthermore, the finding that having children and family impacted on the 
willingness to trade life years has been observed in previous studies as well (90, 92).  
Moreover, an important consideration in this discussion, perhaps in particular for the use of 
TTO as a direct method for valuing currently experienced health, is that several interview 
participants questioned what purpose this question could serve in health care. In previous 
literature, some concerns have been raised regarding ethical considerations of experience-
based valuations, for example if it is possible to justify that patients in severe health 
conditions are asked to imagine being dead or in full health (93). Interestingly, our findings 
showed that “full health” provoked more thoughts and feelings than “dead”. One of the two 
participants who refused to answer the question said that the question awakened only feelings 
of hopelessness. In addition to that the TTO method should be accepted by the respondents, 
another consideration is to what extent this question can be broadly used across different 
patient populations.  
6.3 IMPLICATIONS FOR POLICY, PRACTICE, AND RESEARCH 
The findings from this thesis can be discussed further in terms of their implications for policy, 
practice, and research. The overview of EQ-5D in the NQRs represents an important 
contribution to the relatively scarce literature showing real-world examples of how PROMs 
are implemented in routine health care and what purposes they address. Furthermore, this 
case highlights the need for improving the use of routinely collected PROMs data and may 
encourage collaborations and/or initiatives for making use of data based on the examples 
provided in the overview of EQ-5D in the Swedish NQRs.  
The findings from the interview study highlight the importance of using both quantitative and 
qualitative assessments for understanding the responses to PROMs and for capturing the 
patient perspective. One learning outcome from the interview study, which may be 
transferable to future implementations of PROMs, was the desire expressed by patients to 
better understand the purpose for which PROMs data were collected. Overall, the findings 
from the qualitative interviews may contribute to a better understanding of what underlies the 
responses to both the EQ-5D-5L descriptive system, EQ VAS, and to same extent also the 
EQ-5D index, which is based on the TTO valuation method. Concerning the direct and 
indirect methods for health state valuation, the variations in interpretations (e.g. time 
perspectives and reference points) call into question their interchangeable use in health 
economic models and in decision-making.  
Several implications may be discussed in relation to the findings from the two register-based 
studies. First, the study examining the measurement properties of the two EQ-5D versions 
indicated that there are advantages to using EQ-5D-5L over EQ-5D-3L specifically for 
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patients with a major amputation of a lower limb. As a consequence of improved 
performance in terms of informativity and validity, the change from EQ-5D-3L to EQ-5D-5L 
in SwedeAmp has likely contributed to more accurate and detailed information about the 
severity of problems experienced by patients. This finding may also be transferable to other 
patient populations experiencing similar problems related to the musculoskeletal system. 
Second, relatively large improvements in HRQoL were observed for patients undergoing 
ECT for unipolar or bipolar major depression, yet there was no indication of a robust 
statistical relationship between pulse width at first ECT session and HRQoL after ECT. Still, 
there may be consequences not captured by the selected outcome measure or by the study 
design. Other treatment parameters could be further explored to optimize the treatment effects 
for patients treated with ECT.  
Some findings from this thesis may also be used to inform future initiatives for implementing 
EQ-5D in routine health care. Although EQ-5D is widely adopted in health economic 
evaluations, the studies and examples provided in this thesis revealed several areas of use 
beyond that purpose. The added value of introducing EQ-5D or other generic measures in the 
NQRs may be to capture the wider perspective of the impact on patients’ HRQoL, as shown 
in Study III and Study IV. Moreover, there are several opportunities associated with EQ-5D 
data already collected. A specific suggestion for further research is to explore the 
measurement properties of different PROMs by taking advantage of the simultaneous 
administration of several measures. As previously mentioned, satisfactory measurement 
properties are key considerations for making meaningful interpretations and making use of 
PROMs data. In addition, the relatively large samples of patients included in the registries 
enable other analyses of routinely collected data, including reference data (e.g. for populating 
health economic models) for defined patient populations or associated with specific 
treatments, side effects, or by clinically relevant subgroups.  
Making use of PROMs routinely collected in health care is a research area still under 
development, and several challenges remain. By design, this thesis has revealed if, and to 
what extent, routinely collected EQ-5D data have been used. Nevertheless, it provides limited 
guidance regarding how, when, and why the implementation of EQ-5D and other PROMs 
works as intended. Based on the findings from this thesis, several recommendations for future 
research can be made. Most importantly, more research is needed to better understand 
motives and requirements for making use of data. For example, future studies could use the 
case of EQ-5D in the Swedish NQRs to examine opportunities for and barriers to making use 
of data to improve health care, and ultimately, health outcomes. Further, although Study II 
contributed to increased understanding of patients’ thoughts when responding to the 
questionnaires, future studies could further explore ways in which the use of routinely 
collected EQ-5D data can be useful to patients.  
 
48 
6.4 METHODOLOGICAL CONSIDERATIONS  
In addition to the study limitations addressed in the manuscripts, a few additional 
methodological considerations associated with the case and the specific studies should be 
addressed.  
6.4.1 The case of EQ-5D in the Swedish national quality registries 
There are several strengths to the case adopted for examining the use of PROMs collected in 
routine health care. The NQRs enable structured data collection in health care settings across 
Sweden, and EQ-5D is one of few PROMs widely implemented in several registries. The 
implementation of PROMs in clinical practice is not consistent across groups and settings. 
Rather than studying a specific group or setting, this case enabled an assessment of the ways 
in which routine collection and use of PROMs were implemented across several patient 
populations and conditions. In addition, there are benefits to the use of real-world outcome 
data from the registries for answering specific research questions important to the overall aim 
of contributing to the knowledge about the use of PROMs in routine health care.  
Nevertheless, the case is also associated with some limitations. Although there are several 
benefits to using EQ-5D (e.g, for comparison across groups, assessment of interventions, and 
health economic evaluations), other PROMs or other outcome measures may be more 
suitable for certain purposes (e.g. monitoring health or treatment effects for the individual 
patient). It is likely that registries have included different PROMs for different purposes, for 
example using disease-specific measures for capturing relevant changes in the health of 
individuals, and generic measures for meso- and macro-level analyses and comparisons. 
Study I was essential for understanding the current practices in the collection, presentation, 
and use of EQ-5D data in the Swedish NQRs. It should be noted that the template used for 
data collection was developed based on previous experiences and discussions among the 
authors and collaborators. Thus, the results regarding different presentations and use of data 
may have been influenced by the examples provided in the template. Further, as the template 
did not provide any definitions, the reporting was based on the definitions used by the 
respondents. In case of future studies, it may be beneficial to apply a theoretical framework as 
a basis for developing examples and to have clear definitions of the categories representing 
different types of use of data in the correspondence with the registries. Furthermore, a 
restriction to having the registry organizations as the primary sources of information is that 
the findings regarding the use of data for follow-up, quality improvement, and decision-
making may not be exhaustive. For example, the health care providers may have used EQ-5D 
data for purposes that the registry representatives were unaware of.  
6.4.2 Primary data collection: Study II 
Several methodological considerations relate to the sampling and data collection in the 
qualitative interview study. It should be noted that the patient population chosen for the 
interviews was not included in any of the registries with ongoing collection and use of  
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EQ-5D data. If the aim of this study had been to explore the patient perspective of making 
use of EQ-5D data, recruitment of patients included in one of the NQRs with ongoing EQ-5D 
collection could have been a more suitable strategy. Nevertheless, for the research question 
explored in this study, the chosen approach may have better reflected patients’ initial 
reactions to the questionnaires. 
As mentioned in the publication, a challenge with the chosen interview technique is that it 
depends on the interviewee’s ability to articulate his/her thoughts. In addition, the interview 
participants were not presented with details regarding a specific purpose or setting in which 
the health assessments could be distributed. Speculatively, the finding demonstrating that 
participants reflected on the purpose of measurement might have been less clear if they had 
received more detailed information prior to or during the interviews.  
Lastly, several actions were taken to enable assessments of the credibility of study findings 
(94). For example, the publication included descriptions of the study context, the sampling 
and recruitment strategy, background characteristics of the study participants, quotes from the 
interviews, and an overview and examples of the data analysis. In addition, some details 
about myself as a researcher were provided. Still, it should be noted that the interviewer plays 
an active role in the research process and perspectives, for example by having certain 
characteristics, experiences, and preconceptions of the specific research question (95). As a 
tool for reflection, a personal logbook was used for taking notes regarding ideas and 
impressions after each interview, and regarding the need for additional sampling.  
6.4.3 Secondary data collection: Study III and Study IV 
Although there are many potential benefits from assessing real-world data from registries, it 
is associated with certain limitations. The variability of observational data reflects real-world 
practices, which is desirable when describing current processes and outcomes, and for 
making decisions related to health care. However, this variability of the data, for example in 
terms of time intervals, missing data, and changes in treatments and risk factors, creates 
certain challenges for research or evaluative purposes (28). The information available from 
the NQRs made it possible to examine and adjust for certain differences in demographic and 
clinical characteristics. Furthermore, the reason for exploring IPWRA in Study IV was to 
adjust for the possible imbalances between the three treatment groups. 
Still, some analyses based on registry data may be challenging. In general, the exact reasons 
for missing data in registries are unknown. Especially in Study III, we discussed whether 
analyses of feasibility could be performed using registry data. In the case of SwedeAmp, the 
registry had included a variable indicating the reason for not responding to EQ-5D, which 
enabled analyses of feasibility. Furthermore, a challenge related to the use of a retrospective 
study design was that the measurement properties of the EQ-5D versions could only be 
examined in separate subsamples as the two versions had been administered during separate 
time periods. Given this design, the research team have had discussions regarding the extent 
to which the analyses reflected differences in measurements or differences between 
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subsamples. At very least, the use of several measures and multiple tests was considered to 
increase the likelihood of identifying advantages and disadvantages of the two EQ-5D 
versions. In addition, the analyses of convergent validity were less influenced by the use of 
separate subsamples, as the correlation between two measures was examined at the same 
time-points for the same individuals.  
Although the use of registries has the advantage of covering samples that are more 
representative of the target population, the inclusion criteria of having responded to EQ-5D 
may have contributed to sampling of a certain subgroup. For example, the patients included 
in the study samples may have had better health than those who were unable to respond to 
PROMs at baseline or at follow-up. Furthermore, although the variables are common for all 
units that contribute with data to the registry, registration is not mandatory. There are several 
sources of both measured and unmeasured variation, for example in terms of the exact time 
for follow-up (reflecting variations in patient’s actual health care visits) and possibly also in 
the instructions and assistance provided when reporting one’s own health using PROMs.  
Lastly, some methodological choices concerning the EQ-5D instruments should be 
addressed. Both the descriptive system and the value sets play a role in the sensitivity and 
discriminatory power of EQ-5D (57). The Swedish version of EQ-5D and value sets for UK 
were applied in all studies. The value sets were chosen to facilitate comparison between  




Through the use of a specific case, the studies included in this thesis have examined several 
aspects important in the use of PROMs collected in routine health care. The thesis has 
presented findings that contribute to the understanding of the use of PROMs data routinely 
collected in the Swedish NQRs, considerations in the choice of EQ-5D version in specific 
populations, and ways in which EQ-5D data may be used to assess specific interventions.  
The findings demonstrated that EQ-5D data, often in combination with disease-specific 
measures, were collected across a variety of patient populations and interventions covered by 
the Swedish NQRs. EQ-5D was most frequently administered in registries targeting 
conditions related to the musculoskeletal system. For patients with a major amputation of a 
lower limb, the results indicated that there were several advantages to the use of EQ-5D-5L 
over the use of EQ-5D-3L. Furthermore, the thesis revealed real-world outcomes after ECT 
in patients with unipolar or bipolar depression. Routinely collected EQ-5D data were 
analyzed with the intention to explore ways of optimizing the treatment effect based on a 
specific treatment parameter, yet the results showed no robust associations between pulse 
width and HRQoL after ECT. 
Moreover, the thesis has revealed findings related to the interpretations and thoughts behind 
patients’ responses to EQ-5D-5L, EQ VAS, and TTO. The findings from the interviews 
revealed some variation in the use of time perspectives, comparators and reference points, 
and the aspects considered when completing the three assessments. Furthermore, some 
participants expressed a desire to explain the reasoning behind their responses in a dialogue 
with their health care provider. This qualitative assessment contributes to the understanding 
of EQ-5D results and the use of EQ-5D data, particularly in patients with type 1 diabetes or 
other chronic conditions. 
The case of EQ-5D data in the Swedish NQRs has demonstrated several examples of ways in 
which routinely collected PROMs data may be used, with the ultimate intention to improve 
health care and patient health. While several examples of purposes for which EQ-5D data 
have been used were found, including assessment of interventions, health economic studies, 
quality indicators, benchmarking, quality improvement, and use at the individual patient 
level, a relatively large share of the NQRs reported that collected data were not being used for 
any of these purposes. Importantly, these findings highlight the fact that routine data 
collection alone is insufficient for achieving the potential benefits of using PROMs in health 
care. For future implementations of PROMs in routine health care, it may be useful to further 
explore how routinely collected PROMs data could be of most use to patients and other 
stakeholders, and to further explore prerequisites for making use of routinely collected 
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10.1 APPENDIX A – STUDY I: TEMPLATE FOR DATA COLLECTION 
 
 
Name of registry:  
Contact person: 
Date for the collection of information:  
General information Information for the registry 
What patients are included in the registry?  
How is it decided that they will be included in the registry (at a health 
care visit, at diagnosis, etc.)? 
 
When is the last registration made in the registry for each patient (24 
months after intervention, when the patient dies, etc.)? 
 
What year did the registry start collecting data?  
How many patients are registered in total, and per year?  
What is the estimated coverage?  
How many of all possible clinics in Sweden participate in the 
collection?  
How many of all eligible patients are given the opportunity to 
respond to the questionnaires?  
What is the response frequency? 
 
What background variables are registered for each patient (e.g., sex, 
age, geographical area, ethnicity, socioeconomics, marital status, 
education)? 
 
What background information is registered regarding the patients’ 
disease? 
 
What diagnostic tests and treatments are registered for the patients?  
Collection of PROMs data 





Which version of EQ-5D are you using? 
• Which version (e.g., EQ-5D-3L, EQ-5D-5L)? 
• Is EQ VAS included? 
 
What value set are you using to calculate the EQ-5D index?  
What other PROM instruments are you using?  
How many EQ-5D measurements do you have in total? For how 
many patients have you registered EQ-5D data, per year? 
 
When did you start collecting EQ-5D data (year, month)?  
Are you measuring once or several times per patient? 
When are data collected (e.g., pre-post treatment, at all visits, at 
follow-up at 3, 6, 9 months, or when patients do their own 
registration at home)? 
 
Administration of PROMs 
How are data collected (e.g. through a paper questionnaire, web 
survey, or face-to-face interviews)?  
If interview, who is doing the interview? 
 
Are patients responding themselves or are other respondents acting as 
proxies? 
 
Use of PROMs for quality improvement and decision-making 
How are PROM data made available to decision makers (patients, 
clinicians, directors, politicians)? 
• Individual feedback to the patient (e.g., instantaneous or at 
follow-up)? 
• Individual feedback for shared decision making, or decision 
support to the patient and clinicians? 
• Aggregated feedback in clinical setting to the patient? 
• Aggregated feedback in clinical setting to the health care 
professionals? 
• Aggregated feedback, other (e.g., webpage or annual 
report)? 
• Research (in what publications?) Registry-based 




How are PROMs data currently analyzed and used? 
• Quality improvement (examples)? 
• Guidelines and/or recommendations? 
• Benchmarking? 
• Evaluation of treatment/intervention effects? 
• Health economic evaluations? 
 
 
10.2 APPENDIX B – STUDY II: INTERVIEW GUIDE 
The semi-structured interview guide was originally in Swedish. 
 
Introductory questions 
Can you tell me how long you have had diabetes? 
 How did you first notice? 
 How long did it take to find out what it was? 
Do you have any other illness? 
 
Think aloud: EQ-5D 
I’m interested in knowing how you think when you fill out a questionnaire about your health 
today. Can you please describe your thoughts out loud while you respond to this 
questionnaire? 
Examples of probing questions. Can you tell me more about your thoughts regarding, e.g.: 
- The different response options in the questionnaire 
- Dimensions that seem more or less important/relevant  
- The questions combining several aspects, i.e., pain/discomfort, anxiety/depression 
 
Think aloud: EQ VAS 
Can you please describe your thoughts out loud while you respond to this questionnaire? 
Examples of probing questions. Can you tell me more about your thoughts regarding, e.g.: 
- Best/worst imaginable health state 
- What it would take to choose a higher/lower score 




Think aloud: Time trade-off 
Can you please describe your thoughts out loud while you respond to this questionnaire? 
Examples of probing questions. Can you tell me more about your thoughts regarding, e.g.: 
- How you come up with the number of years in full health that you think is of equal 
value to living 10 years in your current health state 
- Full health 
- Reasons for not wanting to give up any life years 
- Imagining ten years left to live 
 
Closing questions 
If we had done the same interview a week or a month ago, how would you have answered 
these questions? 
I have asked all my questions. Is there anything you would like to add or elaborate on? 
 
10.3 APPENDIX C – STUDY IV: RESULTS OF ADDITIONAL ANALYSES 
See next page.  
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